PharmaVoice’s Crystal Ball: Industry shifts in R&D, policy and clinical trials

<!DOCTYPE html> <html class="no-js" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns# fb: http://ogp.me/ns/fb#"> <head> <meta charset="utf-8"> <meta http-equiv="x-ua-compatible" content="ie=edge"> <meta name="viewport" content="width=device-width, initial-scale=1.0"> <title>PharmaVoice’s Crystal Ball: Industry shifts in R&D, policy and clinical trials | PharmaVoice</title> <meta name="description" content="News for pharmacy pros"/> <meta name="sailthru.tags" content="pharmavoice,type-newspost,pharmavoice-biotech,pharmavoice-commercialization,pharmavoice-leadership,pharmavoice-patient,pharmavoice-pharma,pharmavoice-policy-regulation,pharmavoice-research-development,pharmavoice-tag-clinical-trials,pharmavoice-tag-commercial-categ,pharmavoice-tag-drug-development,pharmavoice-tag-policy-regulator"/> <meta property="fb:pages" content="212905108768849"> <script data-cfasync="false"> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('consent','default',{ 'ad_storage':'denied', 'analytics_storage':'denied', 'ad_user_data':'denied', 'ad_personalization':'denied', 'personalization_storage':'denied', 'functionality_storage':'granted', 'security_storage':'granted', 'wait_for_update': 500 }); gtag("set", "ads_data_redaction", true); </script> <script data-cfasync="false" src="https://cmp.osano.com/AzqdtLT8Mqkut2TZ/bdeb2f70-056f-4937-961a-e9db412e4c7a/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script data-cfasync="false"> window.Osano.cm.addEventListener("osano-cm-script-blocked", function (item) { console.log("Script blocked: " + item); }); window.Osano.cm.addEventListener("osano-cm-cookie-blocked", function (item) { console.log("Cookie blocked: " + item); }); </script> <script> window.dive_location = "NonEU"; window.dive_limit_data_processing = false; </script>  <link rel="icon" type="image/x-icon" sizes="any" href="/favicon.ico?v=2" /> <link rel="apple-touch-icon" sizes="180x180" href="/apple-touch-icon.png?v=2"> <link rel="icon" type="image/png" sizes="32x32" href="/favicon-32x32.png?v=2"> <link rel="icon" type="image/png" sizes="16x16" href="/favicon-16x16.png?v=2"> <link rel="manifest" href="/site.webmanifest?v=2"> <link rel="mask-icon" href="/safari-pinned-tab.svg?v=2" color="#5bbad5"> <meta name="msapplication-TileImage" content="/mstile-150x150.png?v=2"> <meta name="msapplication-TileColor" content="#603cba"> <meta name="theme-color" content="#ffffff"> <link rel="alternate" type="application/rss+xml" title="PharmaVoice - Latest News Feed" href="https://www.pharmavoice.com/feeds/news/"/> <link rel="canonical" href="https://www.pharmavoice.com/news/pharma-crystal-ball-2025-rd-policy-innovation-drug-clinical/736935/"/> <meta name="title" content="PharmaVoice’s Crystal Ball: Industry shifts in R&D, policy and clinical trials" /> <meta name="medium" content="news" /> <meta name="date" content="2025-01-10" /> <meta name="twitter:card" content="summary_large_image"> <meta name="twitter:domain" content="PharmaVoice"> <meta name="twitter:site" content="@PharmaVoice"> <meta property="og:title" name="og:title" content="PharmaVoice’s Crystal Ball: Industry shifts in R&D, policy and clinical trials" /> <meta property="og:site_name" name="og:site_name" content="PharmaVoice" /> <meta property="og:type" name="og:type" content="article" /> <meta name="article_date_original" content="Friday, January 10, 2025, 07:50 AM" /> <meta property="og:url" name="og:url" content="https://www.pharmavoice.com/news/pharma-crystal-ball-2025-rd-policy-innovation-drug-clinical/736935/" /> <meta property="og:image" name="og:image" content="https://imgproxy.divecdn.com/1j8jWljK99Ta2sE8WNG6YFU8SNjkf5taLeCsyxRV_eI/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTg3Nzk3NzE1XzEuanBn.webp" /> <meta property="og:description" name="og:description" content="Coming changes that could impact pharma from drug development to launch." /> <meta name="sailthru.date" content="2025-01-10T07:50:50" /> <meta name="sailthru.expire_date" content="2034-12-29T07:50:50" /> <meta name="sailthru.author" content="Meagan Parrish" /> <meta name="sailthru.image.full" content="https://imgproxy.divecdn.com/1j8jWljK99Ta2sE8WNG6YFU8SNjkf5taLeCsyxRV_eI/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTg3Nzk3NzE1XzEuanBn.webp" />  <meta name="sailthru.image.thumb" content="https://imgproxy.divecdn.com/fLJ66elN2OxL39k6lvNNGVyTeKvdCJf_gG8_o0bCcYo/g:ce/rs:fit:106:60/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTg3Nzk3NzE1XzEuanBn.webp" />  <meta name="sailthru.description" content="Coming changes that could impact pharma from drug development to launch." /> <link rel="stylesheet" href="/static/css/pharmavoice_app.css?305715190225"> <script> // Initialize dataLayer empty array for GTM events window.dataLayer = window.dataLayer || []; window.dataLayer.push({ 'site': 'PharmaVoice', }); // wrapper function to push GTM events to dataLayer pushGTMEvent = (eventObject) => { // if window.datalayer is not defined, then set to an empty array window.dataLayer.push(eventObject); }; </script>  <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-55G8WRR');</script>  <script> let eventParams = {}; eventParams.author = "Meagan Parrish"; eventParams.date_published_readable = "2025-01-10"; eventParams.post_type = "Opinion"; eventParams.tags = "Clinical Trials, Commercial, Drug Development, Policy & Regulatory"; eventParams.topics = "Biotech, Commercialization, Leadership, Patient, Pharma, Policy & Regulation, Research & Development"; eventParams.clone = "False"; eventParams.storyline = "Year in Preview"; const gtmEventObject = { event: 'page.content', 'page.content': { v:11, // seer version ...eventParams } }; window.pushGTMEvent(gtmEventObject); </script> <script type="module" src="/static/js/dist/lyticsHelper.bundle.js?325815190225" ></script> <script type="text/javascript" src="/static/js/ad_blocker_recovery.js?160016291122"></script>  <script async src="https://fundingchoicesmessages.google.com/i/pub-8553262192892817?ers=1" nonce="RORABhIXgMhQdZXbks8fZQ"></script> <script nonce="RORABhIXgMhQdZXbks8fZQ">(function() {function signalGooglefcPresent() {if (!window.frames['googlefcPresent']) {if (document.body) {const iframe = document.createElement('iframe'); iframe.style = 'width: 0; height: 0; border: none; z-index: -1000; left: -1000px; top: -1000px;'; iframe.style.display = 'none'; iframe.name = 'googlefcPresent'; document.body.appendChild(iframe);} else {setTimeout(signalGooglefcPresent, 0);}}}signalGooglefcPresent();})();</script>  <script>(function(){/* Copyright The Closure Library Authors. SPDX-License-Identifier: Apache-2.0 */ 'use strict';var aa=function(a){var b=0;return function(){return b<a.length?{done:!1,value:a[b++]}:{done:!0}}},ba="function"==typeof Object.create?Object.create:function(a){var b=function(){};b.prototype=a;return new b},k;if("function"==typeof Object.setPrototypeOf)k=Object.setPrototypeOf;else{var m;a:{var ca={a:!0},n={};try{n.__proto__=ca;m=n.a;break a}catch(a){}m=!1}k=m?function(a,b){a.__proto__=b;if(a.__proto__!==b)throw new TypeError(a+" is not extensible");return a}:null} var p=k,q=function(a,b){a.prototype=ba(b.prototype);a.prototype.constructor=a;if(p)p(a,b);else for(var c in b)if("prototype"!=c)if(Object.defineProperties){var d=Object.getOwnPropertyDescriptor(b,c);d&&Object.defineProperty(a,c,d)}else a[c]=b[c];a.v=b.prototype},r=this||self,da=function(){},t=function(a){return a};var u;var w=function(a,b){this.g=b===v?a:""};w.prototype.toString=function(){return this.g+""};var v={},x=function(a){if(void 0===u){var b=null;var c=r.trustedTypes;if(c&&c.createPolicy){try{b=c.createPolicy("goog#html",{createHTML:t,createScript:t,createScriptURL:t})}catch(d){r.console&&r.console.error(d.message)}u=b}else u=b}a=(b=u)?b.createScriptURL(a):a;return new w(a,v)};var A=function(){return Math.floor(2147483648*Math.random()).toString(36)+Math.abs(Math.floor(2147483648*Math.random())^Date.now()).toString(36)};var B={},C=null;var D="function"===typeof Uint8Array;function E(a,b,c){return"object"===typeof a?D&&!Array.isArray(a)&&a instanceof Uint8Array?c(a):F(a,b,c):b(a)}function F(a,b,c){if(Array.isArray(a)){for(var d=Array(a.length),e=0;e<a.length;e++){var f=a[e];null!=f&&(d[e]=E(f,b,c))}Array.isArray(a)&&a.s&&G(d);return d}d={};for(e in a)Object.prototype.hasOwnProperty.call(a,e)&&(f=a[e],null!=f&&(d[e]=E(f,b,c)));return d} function ea(a){return F(a,function(b){return"number"===typeof b?isFinite(b)?b:String(b):b},function(b){var c;void 0===c&&(c=0);if(!C){C={};for(var d="ABCDEFGHIJKLMNOPQRSTUVWXYZabcdefghijklmnopqrstuvwxyz0123456789".split(""),e=["+/=","+/","-_=","-_.","-_"],f=0;5>f;f++){var h=d.concat(e[f].split(""));B[f]=h;for(var g=0;g<h.length;g++){var l=h[g];void 0===C[l]&&(C[l]=g)}}}c=B[c];d=Array(Math.floor(b.length/3));e=c[64]||"";for(f=h=0;h<b.length-2;h+=3){var y=b[h],z=b[h+1];l=b[h+2];g=c[y>>2];y=c[(y&3)<< 4|z>>4];z=c[(z&15)<<2|l>>6];l=c[l&63];d[f++]=""+g+y+z+l}g=0;l=e;switch(b.length-h){case 2:g=b[h+1],l=c[(g&15)<<2]||e;case 1:b=b[h],d[f]=""+c[b>>2]+c[(b&3)<<4|g>>4]+l+e}return d.join("")})}var fa={s:{value:!0,configurable:!0}},G=function(a){Array.isArray(a)&&!Object.isFrozen(a)&&Object.defineProperties(a,fa);return a};var H;var J=function(a,b,c){var d=H;H=null;a||(a=d);d=this.constructor.u;a||(a=d?[d]:[]);this.j=d?0:-1;this.h=null;this.g=a;a:{d=this.g.length;a=d-1;if(d&&(d=this.g[a],!(null===d||"object"!=typeof d||Array.isArray(d)||D&&d instanceof Uint8Array))){this.l=a-this.j;this.i=d;break a}void 0!==b&&-1<b?(this.l=Math.max(b,a+1-this.j),this.i=null):this.l=Number.MAX_VALUE}if(c)for(b=0;b<c.length;b++)a=c[b],a<this.l?(a+=this.j,(d=this.g[a])?G(d):this.g[a]=I):(d=this.l+this.j,this.g[d]||(this.i=this.g[d]={}),(d=this.i[a])? G(d):this.i[a]=I)},I=Object.freeze(G([])),K=function(a,b){if(-1===b)return null;if(b<a.l){b+=a.j;var c=a.g[b];return c!==I?c:a.g[b]=G([])}if(a.i)return c=a.i[b],c!==I?c:a.i[b]=G([])},M=function(a,b){var c=L;if(-1===b)return null;a.h||(a.h={});if(!a.h[b]){var d=K(a,b);d&&(a.h[b]=new c(d))}return a.h[b]};J.prototype.toJSON=function(){var a=N(this,!1);return ea(a)}; var N=function(a,b){if(a.h)for(var c in a.h)if(Object.prototype.hasOwnProperty.call(a.h,c)){var d=a.h[c];if(Array.isArray(d))for(var e=0;e<d.length;e++)d[e]&&N(d[e],b);else d&&N(d,b)}return a.g},O=function(a,b){H=b=b?JSON.parse(b):null;a=new a(b);H=null;return a};J.prototype.toString=function(){return N(this,!1).toString()};var P=function(a){J.call(this,a)};q(P,J);function ha(a){var b,c=(a.ownerDocument&&a.ownerDocument.defaultView||window).document,d=null===(b=c.querySelector)||void 0===b?void 0:b.call(c,"script[nonce]");(b=d?d.nonce||d.getAttribute("nonce")||"":"")&&a.setAttribute("nonce",b)};var Q=function(a,b){b=String(b);"application/xhtml+xml"===a.contentType&&(b=b.toLowerCase());return a.createElement(b)},R=function(a){this.g=a||r.document||document};R.prototype.appendChild=function(a,b){a.appendChild(b)};var S=function(a,b,c,d,e,f){try{var h=a.g,g=Q(a.g,"SCRIPT");g.async=!0;g.src=b instanceof w&&b.constructor===w?b.g:"type_error:TrustedResourceUrl";ha(g);h.head.appendChild(g);g.addEventListener("load",function(){e();d&&h.head.removeChild(g)});g.addEventListener("error",function(){0<c?S(a,b,c-1,d,e,f):(d&&h.head.removeChild(g),f())})}catch(l){f()}};var ia=r.atob("aHR0cHM6Ly93d3cuZ3N0YXRpYy5jb20vaW1hZ2VzL2ljb25zL21hdGVyaWFsL3N5c3RlbS8xeC93YXJuaW5nX2FtYmVyXzI0ZHAucG5n"),ja=r.atob("WW91IGFyZSBzZWVpbmcgdGhpcyBtZXNzYWdlIGJlY2F1c2UgYWQgb3Igc2NyaXB0IGJsb2NraW5nIHNvZnR3YXJlIGlzIGludGVyZmVyaW5nIHdpdGggdGhpcyBwYWdlLg=="),ka=r.atob("RGlzYWJsZSBhbnkgYWQgb3Igc2NyaXB0IGJsb2NraW5nIHNvZnR3YXJlLCB0aGVuIHJlbG9hZCB0aGlzIHBhZ2Uu"),la=function(a,b,c){this.h=a;this.j=new R(this.h);this.g=null;this.i=[];this.l=!1;this.o=b;this.m=c},V=function(a){if(a.h.body&&!a.l){var b= function(){T(a);r.setTimeout(function(){return U(a,3)},50)};S(a.j,a.o,2,!0,function(){r[a.m]||b()},b);a.l=!0}},T=function(a){for(var b=W(1,5),c=0;c<b;c++){var d=X(a);a.h.body.appendChild(d);a.i.push(d)}b=X(a);b.style.bottom="0";b.style.left="0";b.style.position="fixed";b.style.width=W(100,110).toString()+"%";b.style.zIndex=W(2147483544,2147483644).toString();b.style["background-color"]=ma(249,259,242,252,219,229);b.style["box-shadow"]="0 0 12px #888";b.style.color=ma(0,10,0,10,0,10);b.style.display= "flex";b.style["justify-content"]="center";b.style["font-family"]="Roboto, Arial";c=X(a);c.style.width=W(80,85).toString()+"%";c.style.maxWidth=W(750,775).toString()+"px";c.style.margin="24px";c.style.display="flex";c.style["align-items"]="flex-start";c.style["justify-content"]="center";d=Q(a.j.g,"IMG");d.className=A();d.src=ia;d.style.height="24px";d.style.width="24px";d.style["padding-right"]="16px";var e=X(a),f=X(a);f.style["font-weight"]="bold";f.textContent=ja;var h=X(a);h.textContent=ka;Y(a, e,f);Y(a,e,h);Y(a,c,d);Y(a,c,e);Y(a,b,c);a.g=b;a.h.body.appendChild(a.g);b=W(1,5);for(c=0;c<b;c++)d=X(a),a.h.body.appendChild(d),a.i.push(d)},Y=function(a,b,c){for(var d=W(1,5),e=0;e<d;e++){var f=X(a);b.appendChild(f)}b.appendChild(c);c=W(1,5);for(d=0;d<c;d++)e=X(a),b.appendChild(e)},W=function(a,b){return Math.floor(a+Math.random()*(b-a))},ma=function(a,b,c,d,e,f){return"rgb("+W(Math.max(a,0),Math.min(b,255)).toString()+","+W(Math.max(c,0),Math.min(d,255)).toString()+","+W(Math.max(e,0),Math.min(f, 255)).toString()+")"},X=function(a){a=Q(a.j.g,"DIV");a.className=A();return a},U=function(a,b){0>=b||null!=a.g&&0!=a.g.offsetHeight&&0!=a.g.offsetWidth||(na(a),T(a),r.setTimeout(function(){return U(a,b-1)},50))},na=function(a){var b=a.i;var c="undefined"!=typeof Symbol&&Symbol.iterator&&b[Symbol.iterator];b=c?c.call(b):{next:aa(b)};for(c=b.next();!c.done;c=b.next())(c=c.value)&&c.parentNode&&c.parentNode.removeChild(c);a.i=[];(b=a.g)&&b.parentNode&&b.parentNode.removeChild(b);a.g=null};var pa=function(a,b,c,d,e){var f=oa(c),h=function(l){l.appendChild(f);r.setTimeout(function(){f?(0!==f.offsetHeight&&0!==f.offsetWidth?b():a(),f.parentNode&&f.parentNode.removeChild(f)):a()},d)},g=function(l){document.body?h(document.body):0<l?r.setTimeout(function(){g(l-1)},e):b()};g(3)},oa=function(a){var b=document.createElement("div");b.className=a;b.style.width="1px";b.style.height="1px";b.style.position="absolute";b.style.left="-10000px";b.style.top="-10000px";b.style.zIndex="-10000";return b};var L=function(a){J.call(this,a)};q(L,J);var qa=function(a){J.call(this,a)};q(qa,J);var ra=function(a,b){this.l=a;this.m=new R(a.document);this.g=b;this.i=K(this.g,1);b=M(this.g,2);this.o=x(K(b,4)||"");this.h=!1;b=M(this.g,13);b=x(K(b,4)||"");this.j=new la(a.document,b,K(this.g,12))};ra.prototype.start=function(){sa(this)}; var sa=function(a){ta(a);S(a.m,a.o,3,!1,function(){a:{var b=a.i;var c=r.btoa(b);if(c=r[c]){try{var d=O(P,r.atob(c))}catch(e){b=!1;break a}b=b===K(d,1)}else b=!1}b?Z(a,K(a.g,14)):(Z(a,K(a.g,8)),V(a.j))},function(){pa(function(){Z(a,K(a.g,7));V(a.j)},function(){return Z(a,K(a.g,6))},K(a.g,9),K(a.g,10),K(a.g,11))})},Z=function(a,b){a.h||(a.h=!0,a=new a.l.XMLHttpRequest,a.open("GET",b,!0),a.send())},ta=function(a){var b=r.btoa(a.i);a.l[b]&&Z(a,K(a.g,5))};(function(a,b){r[a]=function(c){for(var d=[],e=0;e<arguments.length;++e)d[e-0]=arguments[e];r[a]=da;b.apply(null,d)}})("__h82AlnkH6D91__",function(a){"function"===typeof window.atob&&(new ra(window,O(qa,window.atob(a)))).start()});}).call(this); window.__h82AlnkH6D91__("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"); </script> <script src="/static/js/jquery_360.min.js?543516150322"></script> <script> // waitForTriggerHandler() is library for queuing up javascript to be stored and then executed when a trigger // function is called. You can push() any number of functions which will be stored unless and until trigger() // is called. Once trigger() is called any future functions that you push() in will be executed immediately. // It is safe to call .trigger() multiple times. Any arguments passed to .trigger() will also be passed along // to the associated function function waitForTriggerHandler() { var function_queue = []; var trigger_arguments = []; this._triggered = false; this.push = function(fn) { if (this._triggered) { // just run it immediately if handler has already been triggered fn.apply(null, trigger_arguments); } else { // otherwise add to the queue to run later function_queue.push(fn); } }; this.trigger = function() { // any arguments passed to trigger(foo, bar, baz) will also be passed along to functions in the queue // first convert any arguments to an array trigger_arguments = Array.prototype.slice.call(arguments); while (function_queue.length){ // for each function in the queue, pop it off and then execute it while passing in any // args that may have been passed to trigger(). function_queue.pop().apply(null, trigger_arguments); // The "null" above is for the value of "this". // See https://developer.mozilla.org/en-US/docs/Web/JavaScript/Reference/Global_Objects/Function/apply#Parameters } this._triggered = true; } } // set up waitToLoadAds handler window.waitToLoadAds = new waitForTriggerHandler(); // We set up the triggers for this below, they depend on whether we're loading lytics on the page </script> <script type="text/javascript"> // This token is here for test_lytics_snippet.py test: lytics-is-enabled window.googletag = window.googletag || {}; googletag.cmd = googletag.cmd || []; // initialize callback (source: https://learn.lytics.com/product-docs/lytics-javascript-tag/receiving-data-from-lytics) !function(){"use strict";var o=window.jstag||(window.jstag={}),r=[];function n(e){o[e]=function(){for(var n=arguments.length,t=new Array(n),i=0;i<n;i++)t[i]=arguments[i];r.push([e,t])}}n("send"),n("mock"),n("identify"),n("pageView"),n("unblock"),n("getid"),n("setid"),n("loadEntity"),n("getEntity"),n("on"),n("once"),n("call"),o.loadScript=function(n,t,i){var e=document.createElement("script");e.async=!0,e.src=n,e.onload=t,e.onerror=i;var o=document.getElementsByTagName("script")[0],r=o&&o.parentNode||document.head||document.body,c=o||r.lastChild;return null!=c?r.insertBefore(e,c):r.appendChild(e),this},o.init=function n(t){return this.config=t,this.loadScript(t.src,function(){if(o.init===n)throw new Error("Load error!");o.init(o.config),function(){for(var n=0;n<r.length;n++){var t=r[n][0],i=r[n][1];o[t].apply(o,i)}r=void 0}()}),this}}(); // custom init + lytics default install tag from https://activate.getlytics.com/connect?aid=2751 // see https://learn.lytics.com/understanding/product-docs/lytics-javascript-tag/configuration#configuration-options var lyticsCid = '44fda7674f94228540d8fba6786f9770'; console.log('You are using the Lytics Prod account'); jstag.init({ src: `https://c.lytics.io/api/tag/${lyticsCid}/latest.min.js`, pageAnalysis: { dataLayerPull: { disabled: true } } }); jstag.pageView(); (function(){ var sailthru_cookie, sailthru_user_id; function read_cookie(cookieName) { var re = new RegExp('[; ]'+cookieName+'=([^\\s;]*)'); var sMatch = (' '+document.cookie).match(re); if (cookieName && sMatch) return unescape(sMatch[1]); return ''; } sailthru_cookie = read_cookie('sailthru_hid'); if (sailthru_cookie.length > 56) { sailthru_user_id = sailthru_cookie.slice(32,56); jstag.send({ st_profile_id: sailthru_user_id }); } })(); jstag.call('entityReady', waitToLoadAds.trigger); setTimeout(waitToLoadAds.trigger, 1000); // also trigger lytics if it's taking too long waitToLoadAds.push(function (lytics_data) { // lytics_data won't be defined if lytics failed to load correctly. In that case // we don't need to set any segments. if (lytics_data && lytics_data.segments) { googletag.cmd.push(function() { googletag.pubads().setTargeting("LyticsSegments", lytics_data.segments); }); } }); function getUID(id) { window.dataLayer.push({'user_id': id}); }; jstag.getid(getUID); </script> <script type="text/javascript" src="/static/js/mailcheck.min.js?192616240919"></script> <script type="text/javascript" src="/static/js/dive_mailcheck.js?192616240919"></script> <script src="/static/js/app.js?262317060225"></script> <script type="text/javascript"> var divecounter_settings = {}; </script> <script type="text/javascript" src="/static/js/divecounter.js?261616040423"></script> <script type="text/javascript"> // Special unbounce signup thing for google traffic. Test with ?test_unbounce in the URL // Note: divecounter must already be loaded. Only enabled on pages that would normally have signup ads // Note: showSignupAd is always off if prestitial is enabled! if ((typeof divecounter !== "undefined") && ($(window).width() > 640)) { var test_unbounce = (window.location.href.indexOf("?test_unbounce")>=0); var force_unbounce = (window.location.href.indexOf("signupbounce=1")>=0) || (window.location.href.indexOf("utm_campaign=Linked-HR")>=0) || (window.location.href.indexOf("utm_source=outbrain")>=0); if (test_unbounce || force_unbounce || (document.referrer.match(/^https?:\/\/(www\.google\.|news\.google\.|t\.co|twitter\.com|www\.facebook\.com)/i) && divecounter.getOption('showSignupAd') && divecounter.canShow(1,1)) ) { // dyanmically load ouibounce.js only on pages where its needed $.getScript("/static/js/ouibounce.min.js?102717100918", function(){ // Once ouibounce.js loads, call the script // We're reusing divecounter's modal instead of OuiBounce's modal code (that's why we pass it 'false') var _ouibounce = ouibounce(false, { aggressive: test_unbounce, // ignore cookie in test mode cookieName: '_viewedOuiBounce', // underscored cookies should be ignored by Varnish callback: function() { divecounter_open_ad(); } }); }); } // end should show unbounce } // end divecounter defined </script> <script type="text/javascript"> function read_cookie(cookieName) { var re = new RegExp('[; ]'+cookieName+'=([^\\s;]*)'); var sMatch = (' '+document.cookie).match(re); if (cookieName && sMatch) return unescape(sMatch[1]); return ''; } var script = document.createElement('script'); script.type = 'text/javascript'; script.async = true; script.addEventListener('load', function(e) { // we only pass the template this context variable on newsposts let informaData = false; informaData = {"canonicalUrl": "https://www.pharmavoice.com/news/pharma-crystal-ball-2025-rd-policy-innovation-drug-clinical/736935/", "pageIsSponsored": false, "pageSponsor": "", "contentAuthor": "Meagan Parrish", "contentPubDate": "2025-01-10 07:50:50", "pageID": "newspost 736935", "pageTitle": "PharmaVoice\u2019s Crystal Ball: Industry shifts in R&D, policy and clinical trials", "pageType": "opinion", "primaryTerm": "Biotech, Commercialization, Leadership, Patient, Pharma, Policy & Regulation, Research & Development", "secondaryTerm": "Clinical Trials, Commercial, Drug Development, Policy & Regulatory"}; if (window.IIRISTracker) { var sailthru_id = read_cookie('sailthru_hid'); if (sailthru_id.length > 56) { sailthru_id = sailthru_id.slice(32,56); } var notProduction = 'False' === 'True'; var domain = 'www.pharmavoice.com'.split('.')[1]; // on non-prod environment, there is specific collector domain to send the data to. var cDomain = notProduction ? 'com-informa-prod1.mini.snplow.net' : 'c.' + domain + '.com' // removed .com previous line var cfg = { config: { td: {}, snowplow: { context: {} } } }; cfg.config.idsource = 'sailthruid'; cfg.config.snowplow.appId = domain; cfg.config.snowplow.cDomain = cDomain; cfg.config.td.lob = 'it'; cfg.config.td.domain = domain; cfg.config.snowplow.contentTagEnabled = !!informaData cfg.config.snowplow.context = informaData window.IIRISTracker.initConfig(cfg); window.IIRISTracker.setTrackingUID(sailthru_id); var irisEvt = new Event('trackerLoaded'); window.dispatchEvent(irisEvt); } else { window.addEventListener('trackerLoaded', function(evt) { if(window.IIRISTracker) { window.IIRISTracker.setTrackingUID(sailthru_id); } }); } }); script.src = 'https://static.iris.informa.com/widgets/v3.0/iris-t.js'; document.getElementsByTagName('head')[0].appendChild(script); </script> <script type="text/javascript"> jQuery.browser = {}; (function () { jQuery.browser.msie = false; jQuery.browser.version = 0; if (navigator.userAgent.match(/MSIE ([0-9]+)\./)) { jQuery.browser.msie = true; jQuery.browser.version = RegExp.$1; } })(); </script>  <script type="text/javascript" src="/static/js/jquery.simplemodal.divefork.min.js?093716120922"></script> <style> /* dynamic style overrides based on DB go here*/ </style> <meta name="sailthru.title" content="PharmaVoice’s Crystal Ball: Industry shifts in R&D, policy and clinical trials" /> <meta name="sailthru.post_type" content="Opinion" /> <meta name="sailthru.dive_awards" content="False" /> <meta name="sailthru.post_updated" content="False" /> <meta name="lytics:topics" content="Clinical Trials, Commercialization, Policy & Regulation, Drug Development, Biotech, Policy & Regulatory, Commercial, Pharma, Research & Development, Patient, Leadership" /> <meta name="robots" content="max-image-preview:large"> <meta name="news_keywords" content="Biotech,biotech,Commercialization,commercialization,Leadership,leadership,Patient,patient,Pharma,pharma,Policy & Regulation,policy-regulation,Research & Development,research-development"/> <script type="text/javascript"> /** Stolen from http://stackoverflow.com/questions/24816/escaping-html-strings-with-jquery **/ $(document).ready(function () { //"Tweet this" pullquote sections // This is used in the processing of 'tweet this' pull quotes function escapeHtml(string) { var entityMap = { "&": "&", "<": "<", ">": ">", '"': '"', "'": ''', "/": '/' }; return String(string).replace(/[&<>"'\/]/g, function (s) { return entityMap[s]; }); } // Process the twitter pullquote sections: // * create the link // * create the text ('tweet this quote') for the link $(".pquote").each(function (index) { var j_words; if ($(this).data('twitter-text') != 'undefined') { j_words = $(this).children('.tweetwords').first(); } else { j_words = $(this).data('twitter-text'); } var j_replace = $(this).children('.tweetquote').first(); var clean_text = escapeHtml(j_words.text()); var link_attributes = 'href="https://twitter.com/intent/tweet?text=' + clean_text + '%20https%3A//www.pharmavoice.com/news/pharma-crystal-ball-2025-rd-policy-innovation-drug-clinical/736935/' + '" class="popup button twitter" data-sharebutton="tweet_quote" data-shareusing="twitter"'; var img = '<img src="/static/img/social_icons/twitter-follow-icon.png?102717100918" alt="Share on Twitter" loading="lazy">'; var link = '<a ' + link_attributes + '>Tweet this quote' + img + '</a>'; j_replace.html(link); }); }); </script> <script type="module" src="/static/js/dist/signupReferrer.bundle.js?325815190225" ></script> <script data-cfasync="false" type="text/javascript" src="/static/js/prestitial.js?270116210524"></script> <script async src="https://securepubads.g.doubleclick.net/tag/js/gpt.js"></script> <script src="/static/js/dist/signupDataGam.bundle.js?325815190225"></script> <script type="text/javascript" src="/static/js/dist/adTemplates.bundle.js?325815190225"></script> <script> var eventMethod = window.addEventListener ? "addEventListener" : "attachEvent"; var eventer = window[eventMethod]; var messageEvent = eventMethod == "attachEvent" ? "onmessage" : "message"; // Build the site_logos object to be later referenced in house ads const site_logos = {}; site_logos['diveapi'] = { domain: 'diveapi', site_name: "API Site", alt_text: "API Site logo", is_current_site: false, white: { png: "None", svg: "None", }, black: { png: "None", svg: "None", } }; site_logos['agriculturedive'] = { domain: 'agriculturedive', site_name: "Agriculture Dive", alt_text: "Agriculture Dive logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/agriculture_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/agriculture_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/agriculture_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/agriculture_black.svg", } }; site_logos['automotivedive'] = { domain: 'automotivedive', site_name: "Automotive Dive", alt_text: "Automotive Dive logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/automotive_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/automotive_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/automotive_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/automotive_black.svg", } }; site_logos['bankingdive'] = { domain: 'bankingdive', site_name: "Banking Dive", alt_text: "Banking Dive logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/banking_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/banking_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/banking_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/banking_black.svg", } }; site_logos['biopharmadive'] = { domain: 'biopharmadive', site_name: "BioPharma Dive", alt_text: "BioPharma Dive logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/biopharma_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/biopharma_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/biopharma_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/biopharma_black.svg", } }; site_logos['cfo'] = { domain: 'cfo', site_name: "CFO.com", alt_text: "CFO.com logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/cfodotcom_white.svg", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/cfodotcom_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/cfodotcom_black.svg", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/cfodotcom_black.svg", } }; site_logos['cfodive'] = { domain: 'cfodive', site_name: "CFO Dive", alt_text: "CFO Dive logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/cfo_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/cfo_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/cfo_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/cfo_black.svg", } }; site_logos['ciodive'] = { domain: 'ciodive', site_name: "CIO Dive", alt_text: "CIO Dive logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/cio_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/cio_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/cio_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/cio_black.svg", } }; site_logos['constructiondive'] = { domain: 'constructiondive', site_name: "Construction Dive", alt_text: "Construction Dive logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/construction_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/construction_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/construction_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/construction_black.svg", } }; site_logos['cstoredive'] = { domain: 'cstoredive', site_name: "C-Store Dive", alt_text: "C-Store Dive logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/cstore_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/cstore_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/cstore_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/cstore_black.svg", } }; site_logos['customerexperiencedive'] = { domain: 'customerexperiencedive', site_name: "CX Dive", alt_text: "CX Dive logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/cx_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/cx_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/cx_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/cx_black.svg", } }; site_logos['cybersecuritydive'] = { domain: 'cybersecuritydive', site_name: "Cybersecurity Dive", alt_text: "Cybersecurity Dive logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/cybersecurity_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/cybersecurity_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/cybersecurity_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/cybersecurity_black.svg", } }; site_logos['educationdive'] = { domain: 'educationdive', site_name: "Education Dive", alt_text: "Education Dive logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/education_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/education_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/education_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/education_black.svg", } }; site_logos['esgdive'] = { domain: 'esgdive', site_name: "ESG Dive", alt_text: "ESG Dive logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/esg_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/esg_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/esg_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/esg_black.svg", } }; site_logos['facilitiesdive'] = { domain: 'facilitiesdive', site_name: "Facilities Dive", alt_text: "Facilities Dive logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/facilities_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/facilities_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/facilities_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/facilities_black.svg", } }; site_logos['fashiondive'] = { domain: 'fashiondive', site_name: "Fashion Dive", alt_text: "Fashion Dive logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/fashion_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/fashion_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/fashion_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/fashion_black.svg", } }; site_logos['fooddive'] = { domain: 'fooddive', site_name: "Food Dive", alt_text: "Food Dive logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/food_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/food_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/food_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/food_black.svg", } }; site_logos['grocerydive'] = { domain: 'grocerydive', site_name: "Grocery Dive", alt_text: "Grocery Dive logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/grocery_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/grocery_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/grocery_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/grocery_black.svg", } }; site_logos['healthcaredive'] = { domain: 'healthcaredive', site_name: "Healthcare Dive", alt_text: "Healthcare Dive logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/healthcare_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/healthcare_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/healthcare_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/healthcare_black.svg", } }; site_logos['highereddive'] = { domain: 'highereddive', site_name: "Higher Ed Dive", alt_text: "Higher Ed Dive logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/highered_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/highered_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/highered_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/highered_black.svg", } }; site_logos['hoteldive'] = { domain: 'hoteldive', site_name: "Hotel Dive", alt_text: "Hotel Dive logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/hotel_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/hotel_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/hotel_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/hotel_black.svg", } }; site_logos['hrdive'] = { domain: 'hrdive', site_name: "HR Dive", alt_text: "HR Dive logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/hr_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/hr_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/hr_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/hr_black.svg", } }; site_logos['k12dive'] = { domain: 'k12dive', site_name: "K-12 Dive", alt_text: "K-12 Dive logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/k12_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/k12_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/k12_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/k12_black.svg", } }; site_logos['legaldive'] = { domain: 'legaldive', site_name: "Legal Dive", alt_text: "Legal Dive logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/legal_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/legal_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/legal_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/legal_black.svg", } }; site_logos['manufacturingdive'] = { domain: 'manufacturingdive', site_name: "Manufacturing Dive", alt_text: "Manufacturing Dive logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/manufacturing_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/manufacturing_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/manufacturing_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/manufacturing_black.svg", } }; site_logos['marketingdive'] = { domain: 'marketingdive', site_name: "Marketing Dive", alt_text: "Marketing Dive logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/marketing_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/marketing_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/marketing_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/marketing_black.svg", } }; site_logos['medtechdive'] = { domain: 'medtechdive', site_name: "MedTech Dive", alt_text: "MedTech Dive logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/medtech_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/medtech_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/medtech_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/medtech_black.svg", } }; site_logos['mobilemarketer'] = { domain: 'mobilemarketer', site_name: "Mobile Marketer", alt_text: "Mobile Marketer logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/mobilemarketer_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/mobilemarketer_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/mobilemarketer_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/mobilemarketer_black.svg", } }; site_logos['multifamilydive'] = { domain: 'multifamilydive', site_name: "Multifamily Dive", alt_text: "Multifamily Dive logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/multifamily_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/multifamily_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/multifamily_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/multifamily_black.svg", } }; site_logos['packagingdive'] = { domain: 'packagingdive', site_name: "Packaging Dive", alt_text: "Packaging Dive logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/packaging_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/packaging_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/packaging_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/packaging_black.svg", } }; site_logos['paymentsdive'] = { domain: 'paymentsdive', site_name: "Payments Dive", alt_text: "Payments Dive logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/payments_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/payments_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/payments_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/payments_black.svg", } }; site_logos['pharmavoice'] = { domain: 'pharmavoice', site_name: "PharmaVoice", alt_text: "PharmaVoice logo", is_current_site: true, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/pharmavoice_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/pharmavoice_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/pharmavoice_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/pharmavoice_black.svg", } }; site_logos['proformative'] = { domain: 'proformative', site_name: "Proformative", alt_text: "Proformative logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/proformative_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/proformative_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/proformative_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/proformative_black.svg", } }; site_logos['restaurantdive'] = { domain: 'restaurantdive', site_name: "Restaurant Dive", alt_text: "Restaurant Dive logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/restaurant_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/restaurant_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/restaurant_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/restaurant_black.svg", } }; site_logos['retaildive'] = { domain: 'retaildive', site_name: "Retail Dive", alt_text: "Retail Dive logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/retail_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/retail_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/retail_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/retail_black.svg", } }; site_logos['smartcitiesdive'] = { domain: 'smartcitiesdive', site_name: "Smart Cities Dive", alt_text: "Smart Cities Dive logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/smartcities_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/smartcities_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/smartcities_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/smartcities_black.svg", } }; site_logos['socialmediatoday'] = { domain: 'socialmediatoday', site_name: "Social Media Today", alt_text: "Social Media Today logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/smt_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/smt_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/smt_color.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/smt_color.svg", } }; site_logos['supplychaindive'] = { domain: 'supplychaindive', site_name: "Supply Chain Dive", alt_text: "Supply Chain Dive logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/supplychain_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/supplychain_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/supplychain_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/supplychain_black.svg", } }; site_logos['truckingdive'] = { domain: 'truckingdive', site_name: "Trucking Dive", alt_text: "Trucking Dive logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/trucking_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/trucking_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/trucking_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/trucking_black.svg", } }; site_logos['utilitydive'] = { domain: 'utilitydive', site_name: "Utility Dive", alt_text: "Utility Dive logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/utility_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/utility_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/utility_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/utility_black.svg", } }; site_logos['wastedive'] = { domain: 'wastedive', site_name: "Waste Dive", alt_text: "Waste Dive logo", is_current_site: false, white: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/waste_white.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/waste_white.svg", }, black: { png: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/waste_black.png", svg: "https://d12v9rtnomnebu.cloudfront.net/logo/publications/waste_black.svg", } }; // Get the dive domain and return the dive logo object, or null if it doesn't exist in site_logos function getDivesiteLogoObject(link_url, alt_domain='') { let dive_domain; // Split link URL on 'adurl=' and take what comes after as the ad url const ad_url = decodeURIComponent(link_url.split('adurl=')[1]); // Split on . to get an array of hostname segments const dive_domain_array = new URL(ad_url).hostname.split('.'); // Retrieve the second to last element of the hostname array, which should always be the domain dive_domain = dive_domain_array[dive_domain_array.length - 2] if (alt_domain) { // If alt_domain has been specified, normalize it. i.e. "HR Dive", "http://hrdive.com", etc. => "hrdive" // This will override the link url's domain. dive_domain = alt_domain.replace(/\s+/g, '').replace(/^(https?:\/\/)?(www\.)?|\.com.*|\?.*|#.*/gi, '').toLowerCase(); } // Return the site logos object for this domain if it exists, or null if it does not if (site_logos[dive_domain]) { return site_logos[dive_domain]; } else { // Fallback logo const url_prefix = "https://d12v9rtnomnebu.cloudfront.net/divesite/responsive_ad_assets/small_logos/"; return { domain: 'industrydive', site_name: 'Industry Dive', alt_text: 'Industry Dive logo', white: { svg: url_prefix + 'industrydive-small-white.svg', png: url_prefix + 'industrydive-small-white.png', }, black: { svg: url_prefix + 'industrydive-small-black.svg', png: url_prefix + 'industrydive-small-black.png', } } } } eventer(messageEvent, function (e) { var key = e.message ? "message" : "data"; var data = e[key]; var eventName = data.message || 'ignore'; if (eventName == 'adContentAvailable') { var $ad_element; $ad_element = $('div').filter('[data-container-ad-unit-id="' + data.adUnit + '-' + window.dfp_visibility + '"]'); $ad_element.hide() var nativeAdEditorialSelector = '.sidebar .hybrid-ad-wrapper .native-ad-editorial'; var nativeAdEditorialExists = $(nativeAdEditorialSelector).length > 0; if ( nativeAdEditorialExists ) { $(nativeAdEditorialSelector).closest('.hybrid-ad-wrapper').addClass('native-ad-editorial-sidebar-border'); } // Inline homepage ad $('.feed-item-ad .hybrid-ad-wrapper a').each(function (index, element) { window.updateGamAdUrl(element, 'inline'); }); // Editorial native ad sidebar // NOTE: must go before inline native ad to ensure correct location added $('.sidebar .native-ad.editorial a').each(function (index, element) { window.updateGamAdUrl(element, 'sidebar'); }); // Editorial native ad inline $('.native-ad.editorial a').each(function (index, element) { window.updateGamAdUrl(element, 'inline'); }); // Sidebar ad $('.sidebar .hybrid-ad-wrapper a').each(function (index, element) { window.updateGamAdUrl(element, 'sidebar'); }); } }, false); var googletag = googletag || {}; googletag.cmd = googletag.cmd || []; googletag.cmd.push(function () { var desktopWidth = 1024; if (window.innerWidth >= desktopWidth) { window.dfp_visibility = 'desktop'; } else { window.dfp_visibility = 'mobile'; } var dfpDisplayConfiguration = { "prestitialEnabled": true, "leaderboardEnabled": true, "sidebarAdsEnabled": true, "visibility": window.dfp_visibility }; if (window.dfp_visibility == 'desktop') { if (typeof prestitialAds == 'object' && prestitialAds.pageIsPrestitialEligible()) { googletag.defineSlot('/21662595662/pharmavoice/pharmavoiceprestitial', [[500, 300], [640, 480]], 'paychekgoeshere').addService(googletag.pubads()); } if (dfpDisplayConfiguration.leaderboardEnabled) { googletag.defineSlot('/21662595662/pharmavoice/pharmavoiceleaderboard', [[970, 180], [728, 90], [970, 90]], 'dfp-leaderboard-desktop').addService(googletag.pubads()); googletag.pubads().addEventListener('slotRenderEnded', function (event) { if ((event.slot.getAdUnitPath() === '/21662595662/pharmavoice/pharmavoiceleaderboard' || event.slot.getAdUnitPath() === '/21662595662/pharmavoice/pharmavoiceleaderboard') && !event.isEmpty ) { $(window).blur(function () { if (document.activeElement === $('#dfp-leaderboard-desktop iframe')[0] || document.activeElement === $('#dfp-leaderboard-desktop iframe')[0]) { try { localStorage.setItem('leaderboard_signup_path', document.location.pathname); } catch (e) { // local storage could not be available due to privacy settings or something } } }); } }); } if (dfpDisplayConfiguration.sidebarAdsEnabled) { googletag.defineSlot('/21662595662/pharmavoice/pharmavoicehybrid1', [[300, 250], 'fluid', [160, 600]], 'dfp-hybrid1-desktop').addService(googletag.pubads()); } googletag.defineSlot('/21662595662/pharmavoice/pharmavoicehybrid2', [[300, 250], 'fluid'], 'dfp-hybrid2-desktop').addService(googletag.pubads()); googletag.defineSlot('/21662595662/pharmavoice/pharmavoicehybrid3', [[300, 250], 'fluid'], 'dfp-hybrid3-desktop').addService(googletag.pubads()); googletag.defineSlot('/21662595662/pharmavoice/pharmavoicehybrid4', [[300, 250], 'fluid'], 'dfp-hybrid4-desktop').addService(googletag.pubads()); googletag.defineSlot('/21662595662/pharmavoice/pharmavoicethankyouhybrid1', ['fluid'], 'dfp-thankyouhybrid1-desktop').addService(googletag.pubads()); googletag.defineSlot('/21662595662/pharmavoice/pharmavoicethankyouhybrid2', ['fluid'], 'dfp-thankyouhybrid2-desktop').addService(googletag.pubads()); } else { googletag.defineSlot('/21662595662/pharmavoice/pharmavoicehybrid1', [[300, 250], 'fluid'], 'dfp-hybrid1-mobile').addService(googletag.pubads()); googletag.defineSlot('/21662595662/pharmavoice/pharmavoicehybrid2', [[300, 250], 'fluid'], 'dfp-hybrid2-mobile').addService(googletag.pubads()); googletag.defineSlot('/21662595662/pharmavoice/pharmavoicehybrid3', [[300, 250], 'fluid'], 'dfp-hybrid3-mobile').addService(googletag.pubads()); googletag.defineSlot('/21662595662/pharmavoice/pharmavoicehybrid4', [[300, 250], 'fluid'], 'dfp-hybrid4-mobile').addService(googletag.pubads()); googletag.defineSlot('/21662595662/pharmavoice/pharmavoicethankyouhybrid1', ['fluid'], 'dfp-thankyouhybrid1-mobile').addService(googletag.pubads()); googletag.defineSlot('/21662595662/pharmavoice/pharmavoicethankyouhybrid2', ['fluid'], 'dfp-thankyouhybrid2-mobile').addService(googletag.pubads()); } googletag.pubads().setTargeting("topics", ["Biotech","biotech","Commercialization","commercialization","Leadership","leadership","Patient","patient","Pharma","pharma","Policy & Regulation","policy-regulation","Research & Development","research-development"]); googletag.pubads().setTargeting("tags", ["pharmavoice-tag-clinical-trials","pharmavoice-tag-commercial-categ","pharmavoice-tag-drug-development","pharmavoice-tag-policy-regulator"]); if ((typeof divecounter !== "undefined") && (divecounter.getData().is_subscriber)) { googletag.pubads().setTargeting("is_subscriber", "yes"); } var site = window.location.host; googletag.pubads().setTargeting("site", site); var first_path = window.location.pathname.split( '/' )[1]; googletag.pubads().setTargeting("first_path", first_path); googletag.pubads().setTargeting("newspost_type", "Opinion"); googletag.pubads().setTargeting("articleID", "736935"); googletag.pubads().setTargeting("slug", "pharma crystal ball 2025 rd policy innovation drug clinical"); googletag.pubads().setTargeting("is_sponsored", "false" ); // Don't show skyscraper ads on full-width articles googletag.pubads().setTargeting("show_skyscraper", "true"); // Set ad targeting on the trendline to show the ads designated for it var isTopicPage = window.location.pathname.indexOf('/topic/') !== -1; if(isTopicPage) { googletag.pubads().setTargeting('is_topics_page', 'true'); } googletag.pubads().setCentering(true); googletag.pubads().collapseEmptyDivs(false); // Whether to collapse the slots even before the ads are fetched. googletag.pubads().enableSingleRequest(); googletag.enableServices(); }); </script> <script>window.fallbackAds = '[{\u0022adType\u0022: \u0022editorial_native_ad\u0022, \u0022link\u0022: \u0022/trendline/artificial\u002Dintelligence\u002Dmachine\u002Dlearning/439/?utm_source\u003DPV\u0026utm_medium\u003DNativeFB\u0026utm_campaign\u003DTrendlineFB\u0022, \u0022label\u0022: \u0022Trendline\u0022, \u0022image\u0022: \u0022https://imgproxy.divecdn.com/xhOGzlxOJ7URQmHWg4mv8xI4uubi7ZJkuper1Xey2yg/g:ce/rs:fit:212:100/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMzY4NTQ4NTk1XzEuanBn.webp\u0022, \u0022attribution\u0022: \u0022\u0022, \u0022headline\u0022: \u0022Harnessing the potential of AI in pharma\u0022, \u0022ctaText\u0022: \u0022Access now\u0022, \u0022description\u0022: \u0022After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.\u0022}, {\u0022adType\u0022: \u0022editorial_native_ad\u0022, \u0022link\u0022: \u0022/trendline/commercialization\u002Dmarketing\u002Dsocial\u002Dmedia/480/?utm_source\u003DPV\u0026utm_medium\u003DNativeFB\u0026utm_campaign\u003DTrendlineFB\u0022, \u0022label\u0022: \u0022Trendline\u0022, \u0022image\u0022: \u0022https://imgproxy.divecdn.com/zkvKuMJ3B\u002DslbC3F\u002DkgVzoOg7C5CS6ZERKSS\u002Dq3NveU/g:ce/rs:fit:212:100/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy04NDcyNDgzOTguanBn.webp\u0022, \u0022attribution\u0022: \u0022\u0022, \u0022headline\u0022: \u0022Top market strategies for today\u005Cu2019s pharma landscape\u0022, \u0022ctaText\u0022: \u0022Access now\u0022, \u0022description\u0022: \u0022As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R\u0026D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical.\u005Cu00a0\u0022}, {\u0022adType\u0022: \u0022editorial_native_ad\u0022, \u0022link\u0022: \u0022/trendline/pharma\u002Dtech\u002Dclinical\u002Dtrials/516/?utm_source\u003DPV\u0026utm_medium\u003DNativeFB\u0026utm_campaign\u003DTrendlineFB\u0022, \u0022label\u0022: \u0022Trendline\u0022, \u0022image\u0022: \u0022https://imgproxy.divecdn.com/PsKSibJk\u002D8unDt0PU5PTWlOH9dhtJxvUOJEYNLt6RYI/g:ce/rs:fit:212:100/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDIyODM4MTA1LmpwZw\u003D\u003D.webp\u0022, \u0022attribution\u0022: \u0022\u0022, \u0022headline\u0022: \u0022The latest tech powering clinical trials\u0022, \u0022ctaText\u0022: \u0022Access now\u0022, \u0022description\u0022: \u0022Companies that utilize these emerging technologies wisely are likely to find an edge in the increasingly competitive drug development arena.\u0022}, {\u0022adType\u0022: \u0022editorial_native_ad\u0022, \u0022link\u0022: \u0022/trendline/rare\u002Ddiseases/351/?utm_source\u003DPV\u0026utm_medium\u003DNativeFB\u0026utm_campaign\u003DTrendlineFB\u0022, \u0022label\u0022: \u0022Trendline\u0022, \u0022image\u0022: \u0022https://imgproxy.divecdn.com/I_u8au9WqN8hyzOfMtCQJU6EPeM\u002D5EXb\u002D2_YUn_XcAs/g:ce/rs:fit:212:100/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDY3MjM4OTgxXzEuanBn.webp\u0022, \u0022attribution\u0022: \u0022\u0022, \u0022headline\u0022: \u0022Inside the growing treatment market for rare diseases\u0022, \u0022ctaText\u0022: \u0022Access now\u0022, \u0022description\u0022: \u0022As drug developers find promise in the rare diseases, deals and treatments are on the rise\u0022}]'</script> <script type="module" src="/static/js/dist/onBoardDiagnostics.bundle.js?325815190225" ></script>   <script src="https://d12v9rtnomnebu.cloudfront.net/informa_banner/techtarget-informa-banner.min.js"></script> </head> <body class=" flush-top article-page news topic- biotech topic- commercialization topic- leadership topic- patient topic- pharma topic- policy-regulation topic- research-development "> <techtarget-informa-banner theme="light" language="en" class="no-print"></techtarget-informa-banner>  <a href="#skip-link-target" class="button button--loud skip-nav-link" tabindex="1">Skip to main content</a>  <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-55G8WRR" height="0" width="0" style="display:none;visibility:hidden"> </iframe></noscript>  <div id="prestitial-init" style="display: none;" class="prestitial-init"></div> <div id="prestitial-outer" class="prestitial content-overlay" style="display:none;"> <section class="site-menu" aria-label="Site menu"> <div class="site-menu-inner"> <img src="https://d12v9rtnomnebu.cloudfront.net/logo/publications/pharmavoice_black.svg" alt="PharmaVoice" class="pub-logo"> </div> </section> <section class="paychek-page-wrapper row"> <div class="paychek-button large-4 large-push-8 columns"> <div> CONTINUE TO SITE ➞ </div> </div> <div class="paychek large-8 large-pull-4 columns"> <div id="paychekgoeshere"></div> <script data-cfasync="false" type="text/javascript"> if (typeof prestitialAds !== 'undefined' && prestitialAds.pageIsPrestitialEligible()) { prestitialAds.showOverlay(); } </script> <script type="text/javascript"> if (typeof prestitialAds !== 'undefined' && prestitialAds.pageIsPrestitialEligible()) { prestitialAds.initialize(7); prestitialAds.setPrestitialPossibleCookie(); var prestitial_ad_is_loaded = false; var prestitial_ad_is_empty = false; googletag.cmd.push(function () { googletag.pubads().addEventListener('slotRenderEnded', function (event) { if (event.slot.getAdUnitPath() == '/21662595662/pharmavoice/pharmavoiceprestitial') { if (event.isEmpty || prestitialAds.testingNoAd()) { prestitial_ad_is_empty = true; prestitialAds.closePrestitial(); } else { prestitial_ad_is_loaded = true; $.modal.close(); $('div#prestitial-init').hide(); // hide the all white overlay prestitialAds.setCookie( "_prestitialViewed", (new Date()).getTime(), prestitialAds.daysBetweenPrestitial ); } } }); }); if (prestitialAds.testingNoAd()) { } else { waitToLoadAds.push(function() { googletag.cmd.push(function () { googletag.display('paychekgoeshere'); }); }); } setTimeout( function () { if (!prestitial_ad_is_loaded && !prestitialAds.overrideTimeout()) { if (!prestitial_ad_is_empty) { // if the prestitial is already hidden, then don't hide it again. if (!prestitialAds.prestitialAdIsClosed()) { prestitialAds.closePrestitial(); prestitialAds.logClosePrestitialAdBy('failed'); } } } else if (!prestitialAds.overrideTimeout()) { setTimeout( function () { // if the prestitial is already hidden, then don't hide it again. if (!prestitialAds.prestitialAdIsClosed()) { prestitialAds.closePrestitial(); prestitialAds.logClosePrestitialAdBy('timeout'); } }, prestitialAds.timeoutSeconds() ); } else { } }, 2900 ); prestitialAds.sentPrestitialEligibleEvent(); } else if (typeof prestitialAds !== 'undefined' && !prestitialAds.pageIsPrestitialEligible()){ prestitialAds.closePrestitial(); } </script> </div> </section> </div> <div id="signup-inter" class="modal_dialog" style="display:none;"> <form id="signup-inter-form" class="form-basic" name="signup-inter-form" action="/signup/" method="POST"> <input type="hidden" name="signup_box_location" value="interstitial"> <input type="hidden" name="signup_initial_url_path" value="/"> <h1> Don't miss the most important voices in pharma </h1> <p class="interstitial-text"> Let PharmaVoice's free newsletter keep you informed on what industry leaders are saying, straight from your inbox. </p> <p class="form-error__message" id="interstitial-error"></p> <div id="form-interstitial"> <input type="email" name="email" placeholder="Work email address" class="email" required id="id_385a26_email"> <div id="newsletter-list-section"> </div> <div id="interstitial-consent-container"> <input name="user_consent" value="1" id="id_user_consent" type="checkbox"> <span> By signing up to receive our newsletter, you agree to our <a href="https://www.techtarget.com/terms-of-use/" target="_blank">Terms of Use</a> and <a href="https://www.techtarget.com/privacy-policy/" target="_blank">Privacy Policy</a>. You can unsubscribe at anytime. </span> </div> </div> <input id="signup-inter-submit" class="email_submit submit button" type="submit" data-role="none" value="Subscribe today"> </form> </div>  <div class="leaderboard-wrap"> <div class="hide-small show-large"> <div data-container-ad-unit-id="/21662595662/pharmavoice/pharmavoiceleaderboard-desktop"></div> <div id='dfp-leaderboard-desktop' style="min-height: 90px"> <script> waitToLoadAds.push(function() { googletag.cmd.push(function() { if (window.dfp_visibility == 'desktop') { googletag.display('dfp-leaderboard-desktop'); } }) }); </script> </div> </div> </div> <div class="page-container"> <header role="banner"> <nav id="top" class="site-menu" aria-label="Site menu"> <div class="site-menu-inner">  <div class="pub-logo-wrapper"> <a href="/" class="analytics t-dash-navigation-top"> <img class="pub-logo" src="https://d12v9rtnomnebu.cloudfront.net/logo/publications/pharmavoice_black.svg" alt="PharmaVoice" height="28"> </a> </div>  <div class="menu-content-wrapper"> <ul class="desktop-menu-main"> <li class="pv-top-nav-dropdown-item js-top-nav-item-visible js-top-nav-item-active"> <button class="nav-menu-item topics-dropdown-item analytics t-voices-navigation-top"> Voices <span class="dropdown-toggle-arrow pharmavoice"></span> </button> <ul class="top-nav-dropdown-menu"> <li class="top-nav-dropdown-menu-item"> <a href="/q-and-a" class="nav-menu-item analytics t-voices-navigation-qanda"> Q&A </a> </li> <li class="top-nav-dropdown-menu-item"> <a href="/profiles" class="nav-menu-item analytics t-voices-navigation-profiles"> Profiles </a> </li> <li class="top-nav-dropdown-menu-item"> <a href="/topic/biotech-spotlight/" class="nav-menu-item analytics t-voices-navigation-biotechspotlight"> Biotech Spotlight </a> </li> <li class="/top-nav-dropdown-menu-item"> <a href="/topic/first-90-days/" class="nav-menu-item analytics t-voices-navigation-first90days"> First 90 Days </a> </li> <li class="top-nav-dropdown-menu-item"> <a href="/opinion" class="nav-menu-item analytics t-voices-navigation-opinions"> Opinions </a> </li> </ul> </li> <li class="pv-top-nav-dropdown-item pv-top-nav-dropdown-item-topics"> <button class="nav-menu-item topics-dropdown-item analytics t-topic-navigation-top"> Topics <span class="dropdown-toggle-arrow pharmavoice"></span> </button> <ul class="top-nav-dropdown-menu"> <li class="top-nav-dropdown-menu-item"> <a href="/topic/biotech/" class="nav-menu-item analytics t-topic-navigation-biotech">Biotech</a> </li> <li class="top-nav-dropdown-menu-item"> <a href="/topic/commercialization/" class="nav-menu-item analytics t-topic-navigation-commercialization">Commercialization</a> </li> <li class="top-nav-dropdown-menu-item"> <a href="/topic/leadership/" class="nav-menu-item analytics t-topic-navigation-leadership">Leadership</a> </li> <li class="top-nav-dropdown-menu-item"> <a href="/topic/manufacturing/" class="nav-menu-item analytics t-topic-navigation-manufacturing">Manufacturing</a> </li> <li class="top-nav-dropdown-menu-item"> <a href="/topic/patient/" class="nav-menu-item analytics t-topic-navigation-patient">Patient</a> </li> <li class="top-nav-dropdown-menu-item"> <a href="/topic/pharma/" class="nav-menu-item analytics t-topic-navigation-pharma">Pharma</a> </li> <li class="top-nav-dropdown-menu-item"> <a href="/topic/policy-regulation/" class="nav-menu-item analytics t-topic-navigation-policy-regulation">Policy & Regulation</a> </li> <li class="top-nav-dropdown-menu-item"> <a href="/topic/research-development/" class="nav-menu-item analytics t-topic-navigation-research-development">Research & Development</a> </li> </ul> </li> <li> <a href="/library/" class="nav-menu-item analytics t-library-navigation">Library</a> </li> <li> <a href="/events/" class="nav-menu-item analytics t-events-navigation">Events</a> </li> <li> <a href="/press-release/" class="nav-menu-item analytics t-press-releases-navigation">Press Releases</a> </li> <li class="pv-top-nav-dropdown-item"> <button class="nav-menu-item topics-dropdown-item analytics t-pv100-navigation-top"> PharmaVoice 100 <span class="dropdown-toggle-arrow pharmavoice"></span> </button> <ul class="top-nav-dropdown-menu"> <li class="top-nav-dropdown-menu-item"> <a href="https://www.pharmavoice.com/news/pharmavoice-100-nomination-form/611747/" class="nav-menu-item analytics t-pv100-navigation-nominate"> Nominate </a> </li> <li class="top-nav-dropdown-menu-item"> <a href="/news/pv100-pharma-leaders-executives/726233/" class="nav-menu-item analytics t-pv100-navigation-current100"> 2024 PV100 </a> </li> <li class="top-nav-dropdown-menu-item"> <a href="/news/pharmavoice100-pv100-pharma-leaders/690951/" class="nav-menu-item analytics t-pv100-navigation-past"> 2023 PV100 </a> </li> </ul> </li> </ul>  <a href="/signup/?signup_location=header" class="nav-menu-item nav-signup-button mobile-nav-signup-button analytics t-signup-navigation button"> Sign up </a> <button class="mobile-menu-toggle"> <img src="/static/img/menu_icons/menu.svg?273117231121" alt="menu" loading="lazy"> </button>  <ul class="desktop-menu-sub list-no-bullets"> <li> <button class="nav-menu-item search-button-front search-toggle analytics t-search-navigation-top"> <img src="/static/img/menu_icons/search.svg?320116291121" alt="search" width="16" height="16" loading="lazy"> <span class="sub-link">Search</span> </button> </li> <li> <a href="/signup/?signup_location=header" class="nav-menu-item nav-signup-button desktop-nav-signup-button analytics t-signup-navigation button"> <img src="/static/img/email_icons/mail.svg?273117231121" width="16" height="11" loading="lazy" alt=""> Sign up </a> </li> </ul> </div> </div> </nav> </header> <div class="menu-search js-search-hide"> <div class="menu-search-inner-wrapper row"> <form action="/search/" method="GET"> <label for="search-desktop"> <span class="screen-reader-text search">Search</span> </label> <input id="search-desktop" type="Search" name="q" placeholder="search"> <button type="submit" value="" class="search-button-front analytics t-search-navigation-drawer"> <img src="/static/images/proformative_search_glass_black.svg?231516061021" width="18" height="18" alt="search" loading="lazy"> </button> <img class="close" src="/static/img/menu_icons/close.svg?273117231121" width="16" height="16" loading="lazy" alt="close search"> </form> </div> </div> <script type="module" src="/static/js/dist/pharmavoiceNav.bundle.js?325815190225" ></script> <script type="module" src="/static/js/dist/navSignupHelper.bundle.js?325815190225" ></script> <div class="search-overlay"></div> <div class="page-wrapper"> <div class="page-inner-wrapper" id="skip-link-target"> <div class="row"> <div class="medium-10 medium-centered large-12"> <section id="main-content" class="main-content large-8 columns"> <link rel="preload" as="image" href="https://imgproxy.divecdn.com/BH3I-Mvh5eEUVTqt4CbFYLBZskLlOAkCYr94MXQ7Rhk/g:ce/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTg3Nzk3NzE1XzEuanBn.webp" imagesrcset="https://imgproxy.divecdn.com/Wy_jcHAfdMDe1BKFbRQP2VW6UMF2nyLWZgH-6Rexrfc/g:ce/rs:fill:400:225:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTg3Nzk3NzE1XzEuanBn.webp 400w, https://imgproxy.divecdn.com/rMHRbdDVmvizZBQx6yAgwxqR_BWOkd6lkWzADHJEmRc/g:ce/rs:fill:800:450:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTg3Nzk3NzE1XzEuanBn.webp 800w, https://imgproxy.divecdn.com/BH3I-Mvh5eEUVTqt4CbFYLBZskLlOAkCYr94MXQ7Rhk/g:ce/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTg3Nzk3NzE1XzEuanBn.webp 1200w, https://imgproxy.divecdn.com/xRiwUfNhYCuUP0qehtwpRkPq_-MnekhXQjF1WYIIo3Y/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTg3Nzk3NzE1XzEuanBn.webp 1600w" imagesizes="(min-width: 64em) 60vw, 100vw" alt=""> <article class=""> <div class="first-page-pdf">  <div class="printed-branding"> <span class="promoted-branded-copy">An article from</span> <img src="https://d12v9rtnomnebu.cloudfront.net/logo/printer_friendly/pharmavoice.jpg" alt="site logo"> </div> <div class="article-title-wrapper"> <div class="post-label-wrapper"> <span class="post-label post-label--medium"> Opinion <span class="post-label post-label--slashes">//</span> <span class="post-label post-label--storyline">Year in Preview</span> </span> </div> <h1 class="display-heading-04"> PharmaVoice’s Crystal Ball: Industry shifts in R&D, policy and clinical trials </h1> <p>Coming changes that could impact pharma from drug development to launch.</p> </div> <div class="byline"> <div class="article-byline"> <div class="date date-bottom-border"> <span class="published-info"> Published Jan. 10, 2025 </span> </div> <div class="byline-row "> <div class="author "> <div class="author-row author-row-flex"> <a href="/editors/mparrish/"> <img class="author-img-round analytics t-article-byline-author" src="https://d1b6lhn2ymmy1x.cloudfront.net/journalist-headshots/parrish-meagan-circle-150x150.png" alt="Meagan Parrish's headshot"> </a> <div class="author-name author-name-with-headshot"> <a rel="author" href="/editors/mparrish/" class="analytics t-article-byline-author">Meagan Parrish</a> <span class="author-title">Lead Editor</span> </div> </div> </div> <div class="social-share"> <ul class="social-icon-list"> <li> <a href="http://www.linkedin.com/shareArticle?mini=true&url=https%3A//www.pharmavoice.com/news/pharma-crystal-ball-2025-rd-policy-innovation-drug-clinical/736935/&title=PharmaVoice%E2%80%99s%20Crystal%20Ball%3A%20Industry%20shifts%20in%20R%26D%2C%20policy%20and%20clinical%20trials" aria-label="Share article to Linkedin" class="social-icon analytics t-article-byline-social-linkedin"> <img src="/static/img/social_icons/article_page/linkedin.svg?092716141024" alt="Post to LinkedIn"> <span class="social-icon__text">post</span> </a> </li> <li> <a href="https://www.facebook.com/sharer/sharer.php?u=https%3A//www.pharmavoice.com/news/pharma-crystal-ball-2025-rd-policy-innovation-drug-clinical/736935/" aria-label="Share article to Facebook" class="social-icon analytics t-article-byline-social-facebook"> <img src="/static/img/social_icons/article_page/facebook.svg?440116200824" alt="Share on Facebook"> <span class="social-icon__text">share</span> </a> </li> <li> <a href="https://twitter.com/intent/tweet?text=PharmaVoice%E2%80%99s%20Crystal%20Ball%3A%20Industry%20shifts%20in%20R%26D%2C%20policy%20and%20clinical%20trials%20https%3A//www.pharmavoice.com/news/pharma-crystal-ball-2025-rd-policy-innovation-drug-clinical/736935/%20via%20@PharmaVoice" aria-label="Share article to X/Twitter" class="social-icon analytics t-article-byline-social-twitter"> <img src="/static/img/social_icons/article_page/x.svg?092716141024" alt="Post on X"> <span class="social-icon__text">post</span> </a> </li> <li> <a href="javascript:window.print()" aria-label="Print article" class="social-icon js-social-icon-print"> <img src="/static/img/social_icons/article_page/print.svg?440116200824" alt="Print this page"> <span class="social-icon__text">print</span> </a> </li> <li> <a href="/cdn-cgi/l/email-protection#9ca3cfe9fef6f9ffe8a1ccf4fdeef1fdcaf3f5fff9b9d9aeb9a4acb9a5a5efb9aeacdfeee5efe8fdf0b9aeacdefdf0f0b9afddb9aeacd5f2f8e9efe8eee5b9aeaceff4f5fae8efb9aeacf5f2b9aeacceb9aeaad8b9aedfb9aeacecf3f0f5ffe5b9aeacfdf2f8b9aeacfff0f5f2f5fffdf0b9aeace8eef5fdf0efbafdf1eca7def3f8e5a1f4e8e8ecefb9afddb3b3ebebebb2ecf4fdeef1fdeaf3f5fff9b2fff3f1b3f2f9ebefb3ecf4fdeef1fdb1ffeee5efe8fdf0b1fefdf0f0b1aeacaea9b1eef8b1ecf3f0f5ffe5b1f5f2f2f3eafde8f5f3f2b1f8eee9fbb1fff0f5f2f5fffdf0b3abafaaa5afa9b3" aria-label="Share article with email" class="social-icon analytics t-article-byline-social-email"> <img src="/static/img/social_icons/article_page/email.svg?092716141024" alt="Email this page"> <span class="social-icon__text">email</span> </a> </li> </ul> </div> </div> </div> </div> <figure class="inside_story"> <div class="figure_content article-hero-img"> <img class="" src="https://imgproxy.divecdn.com/BH3I-Mvh5eEUVTqt4CbFYLBZskLlOAkCYr94MXQ7Rhk/g:ce/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTg3Nzk3NzE1XzEuanBn.webp" width="1200" height="675" srcset="https://imgproxy.divecdn.com/Wy_jcHAfdMDe1BKFbRQP2VW6UMF2nyLWZgH-6Rexrfc/g:ce/rs:fill:400:225:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTg3Nzk3NzE1XzEuanBn.webp 400w, https://imgproxy.divecdn.com/rMHRbdDVmvizZBQx6yAgwxqR_BWOkd6lkWzADHJEmRc/g:ce/rs:fill:800:450:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTg3Nzk3NzE1XzEuanBn.webp 800w, https://imgproxy.divecdn.com/BH3I-Mvh5eEUVTqt4CbFYLBZskLlOAkCYr94MXQ7Rhk/g:ce/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTg3Nzk3NzE1XzEuanBn.webp 1200w, https://imgproxy.divecdn.com/xRiwUfNhYCuUP0qehtwpRkPq_-MnekhXQjF1WYIIo3Y/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTg3Nzk3NzE1XzEuanBn.webp 1600w" sizes="(min-width: 64em) 60vw, 100vw" alt="2025 pills" > </div> <figcaption class="inside_story_caption"> <span class="source_text"> Stock via Getty Images </span> </figcaption> </figure> </div> <div class="row"> <div class="article-large-12 columns article-wrapper"> <div class="print-wrapper"> <div class="add-drop-cap large medium article-body"> <div class="text-to-speech"> <button class="text-to-speech__button button"> <img class="text-to-speech__button__icon" src="/static/images/audio_icon.svg?482016190122" alt=""/> Listen to the article <span class="text-to-speech__button__audio-length">26 min</span> </button> <div class="text-to-speech__controls"> <audio controls class="js-text-to-speech" preload="none"> <source src="http://res.cloudinary.com/dmgi9movl/video/upload/q_1/v1737148720/news/text_to_speech/pharma-crystal-ball-2025-rd-policy-innovation-drug-clinical_enco0c.wav" type="audio/mp3"> </audio> <div class="text-to-speech__controls__text"> This audio is auto-generated. Please let us know if you have <a href="/contact/">feedback</a>. </div> </div> </div> <div class="editor-note"> <p>This is the second installment of a two-part series examining pharma’s year ahead. The first installment looked at the various ways<a href="https://www.pharmavoice.com/news/pharma-preview-2025-prediction-ai-drug-discovery/736470/"> AI will shape</a> the industry.</p> </div> <p>Pharma is always rife with medical breakthroughs.</p> <p>In 2024, the industry witnessed a number of significant milestones, including an FDA nod for Iovance Biotherapeutics’ Amtagvi, the first <a href="https://www.pharmavoice.com/news/fda-iovance-til-solid-tumor-cell-therapy/707988/">approved cell therapy</a> targeting solid tumors. Bristol Myers Squibb and Karuna Therapeutics also overcame a long-standing rut in schizophrenia <a href="https://www.pharmavoice.com/news/bms-karxt-schizophrenia-fda-karuna-miller/728227/">with Cobenfy</a>, the first new modality approved for the indication in decades.</p> <p>But behind the scenes, companies face a complex swirl of challenges.</p> <p>The Biden administration is set to announce the next batch of drugs up for <a href="https://www.axios.com/2025/01/08/medicare-drug-price-negotiation-list-biden-trump?utm_source=newsletter&utm_medium=email&utm_campaign=newsletter_axiosvitals&stream=top">price negotiations</a> through the Inflation Reduction Act by Feb. 1, and anxieties over R&D progression still linger under a cloud of the IRA and other financial headwinds such as inflation. In response, leaders are adopting stricter pipeline management strategies, and boosting research ROI will be a top priority.</p> <p>As companies develop the most advanced therapies, the process of conducting clinical trials and then ensuring access to patients when drugs are approved has gotten more complicated.</p> <p>How will these forces shape the future of innovation in pharma next year? Here are the advances industry leaders foresee in drug development, clinical trial tech, policy and more.</p> <div class="hybrid-ad-wrapper show-small hide-large"> <div class="hybrid-ad-inner-wrapper"> <div class="show-small hide-large"> <div data-container-ad-unit-id="/21662595662/pharmavoice/pharmavoicehybrid1-mobile"></div> <div id="dfp-hybrid1-mobile"> <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script> waitToLoadAds.push(function() { googletag.cmd.push(function() { if (window.dfp_visibility == 'mobile' ) { googletag.display('dfp-hybrid1-mobile'); googletag.pubads().addEventListener('slotRenderEnded', function (event) { var adUnitPath = '/21662595662/pharmavoice/pharmavoicehybrid1'; var onProformative = false; if (onProformative && event.slot.getAdUnitPath() === adUnitPath && !event.isEmpty ) { var adUnitPathWithVisibility = adUnitPath + '-mobile'; var selector = '.pf-comments__ad-wrapper [data-container-ad-unit-id="' + adUnitPathWithVisibility + '"]'; if (!$(selector).closest('.pf-comments__ad-wrapper').hasClass('borders')) { $(selector).closest('.pf-comments__ad-wrapper').addClass('borders') } } }); } }); }); </script> </div> </div> </div> </div> <div class="hybrid-ad-wrapper hide-small show-large"> <div class="hybrid-ad-inner-wrapper"> <div class="hide-small show-large"> <div data-container-ad-unit-id="/21662595662/pharmavoice/pharmavoicehybrid2-desktop"></div> <div id="dfp-hybrid2-desktop"> <script> waitToLoadAds.push(function() { googletag.cmd.push(function() { if (window.dfp_visibility == 'desktop' ) { googletag.display('dfp-hybrid2-desktop'); googletag.pubads().addEventListener('slotRenderEnded', function (event) { var adUnitPath = '/21662595662/pharmavoice/pharmavoicehybrid2'; var onProformative = false; if (onProformative && event.slot.getAdUnitPath() === adUnitPath && !event.isEmpty ) { var adUnitPathWithVisibility = adUnitPath + '-desktop'; var selector = '.pf-comments__ad-wrapper [data-container-ad-unit-id="' + adUnitPathWithVisibility + '"]'; if (!$(selector).closest('.pf-comments__ad-wrapper').hasClass('borders')) { $(selector).closest('.pf-comments__ad-wrapper').addClass('borders') } } }); } }); }); </script> </div> </div> </div> </div> <h3 class="standard-heading">Oncology’s next breakthroughs</h3> <p><strong>SERDS could transform patient care</strong></p> <figure class="image-right inside_story"> <div class="figure_content"> <div><img alt="Lillian Smyth" data-imagemodel="172714" src="https://imgproxy.divecdn.com/BD6IWHrUcaRQvavxWd7AmQkagA8wZl2I752xgOxRqkc/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9MaWxsaWFuX1NteXRoX01EX0hlYWRzaG90LmpwZw==.webp"/></div> </div> <figcaption class="inside_story_caption"> <div class="caption_text">Optional Caption</div> <div class="source_text">Permission granted by Eli Lilly</div> <div class="clearfix"> </div> </figcaption> </figure> <p>“In 2025 and beyond, we expect that cancer treatment will continue to evolve to better meet the needs of patients and offer meaningful advances. Particularly exciting are the advances we are seeing with oral selective estrogen receptor degraders (SERDs) in breast cancer, which offers an oral, at-home endocrine therapy option versus a 20-year-old standard-of-care treatment that must be administered via intramuscular injections in a doctor’s office. An oral treatment option gives patients a greater sense of control over their lives and empowers them to manage their cancer without affecting or interrupting their daily routine, including potentially fewer doctor visits and less time traveling to treatment.”<br/> <em>Dr. Lillian Smyth, senior vice president, global development head, breast cancer, Eli Lilly</em></p> <p><strong>Bispecifics will change immuno-oncology therapy</strong></p> <figure class="image-right inside_story"> <div class="figure_content"> <div><img alt="Do Kim headshot" data-imagemodel="172718" src="https://imgproxy.divecdn.com/yloO4tJULjtIkUfM4rXf8yfJr5otGA1dteFj1av6gYg/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9Eb19LaW1fSGVhZHNob3QuanBn.webp"/></div> </div> <figcaption class="inside_story_caption"> <div class="caption_text">Optional Caption</div> <div class="source_text">Permission granted by Water Tower Research</div> <div class="clearfix"> </div> </figcaption> </figure> <p>“In the past decade, checkpoint inhibitors have been widely established as the backbone immunotherapy across multiple tumor types, with other drugs layered on top for greater efficacy and increasingly becoming the standard-of-care in earlier treatment lines across a broad range of tumor types. The new drug class of PD-(L)1/VEGF bispecific antibodies will change the current landscape as more clinical data roll out, validating the improved benefit over first-gen PD-(L)1 inhibitors and setting a new efficacy bar for regulatory approval. The dual mechanism will allow these treatments to expand into cold tumors, where standard immuno-therapies have generally failed.”<br/> <em>Do Kim, senior research analyst, Water Tower Research</em></p> <p><strong>Combo therapies will trigger a shift in care</strong></p> <figure class="image-right inside_story"> <div class="figure_content"> <div><img alt="Judith Klimovsky" data-imagemodel="172719" src="https://imgproxy.divecdn.com/GXlJPBmuDarKL-pSiAcFMvGl028ElMYpn1aZo7KrfLI/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9TY3JlZW5zaG90XzIwMjUtMDEtMDlfYXRfMTEuNTQuMzNfQU0ucG5n.webp"/></div> </div> <figcaption class="inside_story_caption"> <div class="caption_text">Optional Caption</div> <div class="source_text">Permission granted by Genmab</div> <div class="clearfix"> </div> </figcaption> </figure> <p>“The landscape of cancer treatment is poised for a big shift with antibody medicines paving the way by harnessing the power of the human immune system to fight disease. Targeted antibodies, such as antibody drug conjugates and bispecifics, will contribute to a shift in the way many cancers are treated and the landscape will evolve from traditional systemic chemotherapy to targeted combination therapies. With investment in antibody technology likely to continue in 2025, the pharmaceutical and biotech industries have a significant opportunity to leverage this science to develop innovations that will make a meaningful impact.”<br/> <em>Dr. Judith Klimovsky, executive vice president, chief development officer, Genmab</em></p> <p><strong>The cancer R&D pendulum will swing</strong></p> <figure class="image-right inside_story"> <div class="figure_content"> <div><img data-imagemodel="-1" src="https://imgproxy.divecdn.com/jEQNVfizxQWD-WCeiFqa9M4g6iQ0OBMi5RHVyDeZAo0/g:ce/rs:fill:355:425:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9TY3JlZW5fU2hvdF8yMDIzLTAxLTE3X2F0XzExLjMwLjAwX0FNLnBuZw==.webp"/></div> </div> <figcaption class="inside_story_caption"> <div class="caption_text">Optional Caption</div> <div class="source_text">Permission granted by Cartography Bio</div> <div class="clearfix"> </div> </figcaption> </figure> <p>“Pharma, biotech and the VC community will more urgently feel the limitations of the lack of new or novel oncology targets. The current ‘yellow flag’ will begin to turn red as the biopharma industry realizes that the risk-off environment of the past decade has led to an industry in which everybody is working on the same things and the de-risked programs companies have been focused on are being chased by everyone else. </p> <p>The oncology drug development pendulum will swing from late-stage and de-risked assets because it is becoming increasingly hard to stand out in a crowded field where everyone is chasing the same targets.”<br/> <em>Kevin Parker, CEO, co-founder, Cartography Bio</em></p> <p><strong>Early-stage combo trials will expand</strong></p> <figure class="image-right inside_story"> <div class="figure_content"> <div><img alt="Francis Burrows" data-imagemodel="172723" src="https://imgproxy.divecdn.com/7evxDl5DRMfLEW3QTwzdf8WXPtfJ5K49ioEzi4Yp_VA/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9LdXJhX09uY29sb2d5X0ZyYW5jaXNfQnVycm93c19IZWFkc2hvdC5qcGVn.webp"/></div> </div> <figcaption class="inside_story_caption"> <div class="caption_text">Optional Caption</div> <div class="source_text">Permission granted by Kura Oncology</div> <div class="clearfix"> </div> </figcaption> </figure> <p>“With combination therapy at the forefront of innovative cancer treatment, we will see its application earlier in the clinical process. It’ll require some creativity and robust statistical models to validate the approach, but we will likely see combination therapies in more phase 1 trials within a dose escalation model. This approach can potentially save invaluable time for patients through an alternative development timeline, especially when a drug is designed specifically for combination treatment. It’s already become a reality for a small number of trials — specifically within oncology — but it has the potential to expand to more oncology trials in 2025.”<br/> <em>Francis Burrows, chief scientific officer, Kura Oncology</em></p> <div class="hybrid-ad-wrapper show-small hide-large"> <div class="hybrid-ad-inner-wrapper"> <div class="show-small hide-large"> <div data-container-ad-unit-id="/21662595662/pharmavoice/pharmavoicehybrid2-mobile"></div> <div id="dfp-hybrid2-mobile"> <script> waitToLoadAds.push(function() { googletag.cmd.push(function() { if (window.dfp_visibility == 'mobile' ) { googletag.display('dfp-hybrid2-mobile'); googletag.pubads().addEventListener('slotRenderEnded', function (event) { var adUnitPath = '/21662595662/pharmavoice/pharmavoicehybrid2'; var onProformative = false; if (onProformative && event.slot.getAdUnitPath() === adUnitPath && !event.isEmpty ) { var adUnitPathWithVisibility = adUnitPath + '-mobile'; var selector = '.pf-comments__ad-wrapper [data-container-ad-unit-id="' + adUnitPathWithVisibility + '"]'; if (!$(selector).closest('.pf-comments__ad-wrapper').hasClass('borders')) { $(selector).closest('.pf-comments__ad-wrapper').addClass('borders') } } }); } }); }); </script> </div> </div> </div> </div> <div class="hide-small show-large" id="desktop-inline-signup"></div> <h3 class="standard-heading">Drug development trends</h3> <p><strong>Where the industry will see breakthroughs</strong></p> <figure class="image-right inside_story"> <div class="figure_content"> <div><img alt="A man in a blue shirt looks into the camera for a headshot photograph." data-imagemodel="154170" src="https://imgproxy.divecdn.com/DykcUyJN0fIK0s1IqEGP9mOd-zSVB-L2TK-Ssm61bNU/g:nowe:0:78/c:800:451/rs:fit:0:860/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9Sb2JlcnRfbGFuZ2VyLXBvbGFyaXMuanBn.webp"/></div> </div> <figcaption class="inside_story_caption"> <div class="caption_text">Optional Caption</div> <div class="source_text">Permission granted by Lindus Health</div> <div class="clearfix"> </div> </figcaption> </figure> <p>“I anticipate significant advances and clinical trials in the following areas: genetic therapies, particularly RNA-based treatments and gene editing; [and] cell therapies, with a focus on regenerative medicine and cancer-killing cells.</p> <p>And we’ll see the expanding application of artificial intelligence in healthcare.”<br/> <em>Robert Langer, co-founder, Moderna; advisor, Lindus Health</em></p> <p><strong>Drug development will focus on disease remission</strong></p> <figure class="image-right inside_story"> <div class="figure_content"> <div><img data-imagemodel="110336" src="https://imgproxy.divecdn.com/v29rzJRHIplfPIYggjH7aChjiU0oS_duYIsPvv2i60M/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9UYWtfUGF1bF9QZXRlci5qcGc=.webp"/></div> </div> <figcaption class="inside_story_caption"> <div class="caption_text">Optional Caption</div> <div class="source_text">Permission granted by Paul Peter Tak.</div> <div class="clearfix"> </div> </figcaption> </figure> <p>“In 2025, there will be an increasing focus on disease remission as the treatment goal, both in immune-mediated inflammatory diseases and in cancer. For example, in conditions like rheumatoid arthritis and systemic lupus erythematosus, we will see more investigational medicines directed against new therapeutic targets and an increased focus on new modalities, such as CAR-T cells, T cell engagers and bispecific antibodies to improve disease outcomes. In cancer, a key question will be: How can we convert non-responders to immune checkpoint inhibitors into responders? For instance, viral immunotherapies will be used to educate the patients’ immune cells how to specifically recognize the tumor. The field will increasingly focus on combination strategies that can modulate both local and systemic immune responses to control disease.”<br/> <em>Dr. Paul Peter Tak, CEO, president, Candel Therapeutics</em></p> <p><strong>The first tri-specific antibody will be approved</strong></p> <figure class="image-right inside_story"> <div class="figure_content"> <div><img alt="Claes Gustafsson" data-imagemodel="172725" src="https://imgproxy.divecdn.com/05Uy6Mjcpn2u8vEjX8KcKV52S9AN8QU1naV0ZT0gkV8/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9DbGFlc19BVFVNLmpwZWc=.webp"/></div> </div> <figcaption class="inside_story_caption"> <div class="caption_text">Optional Caption</div> <div class="source_text">Permission granted by ATUM Bio</div> <div class="clearfix"> </div> </figcaption> </figure> <p>“Bispecific antibodies have emerged as a transformative drug modality, driven by advancements in protein engineering, multi-ORF cell line development and process development. These innovations have delivered remarkable improvements in specificity and clinical efficacy. To date, 12 bispecific antibodies have gained regulatory approval, with many more in the pipeline. Looking ahead, I predict the regulatory approval of the first tri-specific antibody in 2025, paving the way for an expanding array of non-natural antibody-derived pharmaceutical formats. These formats are engineered for enhanced half-life, reduced cytokine release and other therapeutic benefits. When integrated into combination regimens with immune checkpoint inhibitors or cell therapies, they promise superior outcomes in oncology and immunology while extending their application to infectious diseases and autoimmune disorders.”<br/> <em>Claes Gustafsson, chief commercial officer, co-founder, ATUM Bio</em></p> <p><strong>AI and personalized medicine will transform R&D</strong></p> <figure class="image-right inside_story"> <div class="figure_content"> <div><img alt="Elizabeth Thompson" data-imagemodel="173188" src="https://imgproxy.divecdn.com/PbV-qYEAc5N_HjxKWYQmzCe6EkCeRGF1NGcZ7dS1LC8/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9IZWFkc2hvdF9MaXpUaG9tcHNvbi5qcGc=.webp"/></div> <div> </div> </div> <figcaption class="inside_story_caption"> <div class="caption_text">Optional Caption</div> <div class="source_text">Permission granted by <em>Acadia Pharmaceuticals</em></div> <div class="clearfix"> </div> </figcaption> </figure> <p><span><span><span>“I see two growing trends shaping rare and neuroscience R&D in 2025: the continued use of advanced AI techniques and the expanded deployment of personalized medicine. Advanced AI techniques such as machine learning are transforming vast amounts of real-world data into actionable insights, becoming a critical component of clinical research, and that’s going to both speed and spread. Other fields — perhaps most importantly in the neuro-psychiatric space — are going to move increasingly towards personalized medicine and biological basis of disease. Alzheimer’s disease is an important first step in this direction, with the evolution to requiring biomarker-confirmed diagnoses, and this will move into other areas as the science grows. After elusive promise for years of the potential to develop tailored treatments, I’m optimistic that we increasingly have the tools to make it a reality.”</span></span></span><br/> <em><span><span><span>Dr. Elizabeth H.Z. Thompson, executive vice president, head, R&D, Acadia Pharmaceuticals</span></span></span> </em></p> <p><strong>Spatial biology will bring new discoveries in translational medicine</strong></p> <figure class="image-right inside_story"> <div class="figure_content"> <div><img alt="Miguel Tam" data-imagemodel="172737" src="https://imgproxy.divecdn.com/sl8brY7mbPjzVSdfm7kW30L-EgZTkUhKeehGV6FsEec/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9TY3JlZW5zaG90XzIwMjUtMDEtMDlfYXRfMTIuNDUuNTNfUE0ucG5n.webp"/></div> </div> <figcaption class="inside_story_caption"> <div class="caption_text">Optional Caption</div> <div class="source_text">Permission granted by BioLegend</div> <div class="clearfix"> </div> </figcaption> </figure> <p>“One of the applications that will benefit the most from genomics is the emerging field of spatial biology, which describes the study of cells in the context of the surrounding tissue, how they are located, how they build tissue and the study of their functionality. Under this umbrella, researchers have developed methods to quantify and characterize different molecules, including spatial transcriptomics, spatial proteomics and spatial genomics. There are several methods to detect these molecules, one of them being next-generation sequencing. As technologies evolve, this multiomics approach will become even more accessible and accurate. With improved resolution down to single cells and even single molecules, the genomic component will play a central role, and over the next several years bring important discoveries in translational medicine.”<br/> <em>Miguel Tam, director, strategic marketing, BioLegend </em></p> <p><strong>Metabolomics will step into the spotlight</strong></p> <figure class="image-right inside_story"> <div class="figure_content"> <div><img alt="Andrea Choe" data-imagemodel="172738" src="https://imgproxy.divecdn.com/69nXQ_WO5SQyWCspQgkaW-GdFXaRyqtLRp_9i85SZjw/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9BbmRyZWFfQ2hvZV8tX0hvbG9jbGFyYV9DRU8uanBn.webp"/></div> </div> <figcaption class="inside_story_caption"> <div class="caption_text">Optional Caption</div> <div class="source_text">Permission granted by Holoclara</div> <div class="clearfix"> </div> </figcaption> </figure> <p>“2025 will be the year metabolomics steps into the spotlight, revealing the biological ‘dark matter’ of elusive metabolites. Building on genomics and proteomics, we now have advanced tools and data platforms to uncover critical molecules — ‘needles’ in infinite molecular haystacks. This expansion will redefine therapeutics. Rather than refining old targets, we’ll discover entirely new molecules that complement precision medicine. Just as CRISPR and GLP-1 drugs revolutionized genetic and metabolic therapies, metabolomics will further unlock novel strategies that match the complexity of human biology.”<br/> <em>Dr. Andrea Choe, CEO, co-founder, Holoclara</em></p> <p><strong>Extreme weather will drive infectious diseases</strong></p> <figure class="image-right inside_story"> <div class="figure_content"> <div><img alt="Thomas Lingelbach" data-imagemodel="172739" src="https://imgproxy.divecdn.com/YI60lkISl3sTY4vYS3cP3fNzcqtdvY9EceJ3woZ8ogA/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9TY3JlZW5zaG90XzIwMjUtMDEtMDlfYXRfMTIuNTAuNDdfUE0ucG5n.webp"/></div> </div> <figcaption class="inside_story_caption"> <div class="caption_text">Optional Caption</div> <div class="source_text">Permission granted by Valneva</div> <div class="clearfix"> </div> </figcaption> </figure> <p>“While the impacts of climate change on weather patterns, sea levels and temperatures are broadly acknowledged, the knock-on consequences for public health often go overlooked. Experts foresee more frequent extreme weather events in 2025, which are likely to contribute to increased levels of infectious and water/mosquito-borne diseases worldwide. Coordinated action and proactive collaboration to address the impact of climate change on public health will be crucial to safeguard global health and help prepare for future threats.”<br/> <em>Thomas Lingelbach, CEO, Valneva</em></p> <p><strong>Key readouts will come in the psychedelics space</strong></p> <figure class="image-right inside_story"> <div class="figure_content"> <div><img alt="Mark Rus" data-imagemodel="172751" src="https://imgproxy.divecdn.com/aPKhuhB9zib7vA-FaU-5Qc5cv_v0GAzlWRhJ9BlCkD0/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9NYXJrX1J1c18xLmpwZw==.webp"/></div> </div> <figcaption class="inside_story_caption"> <div class="caption_text">Optional Caption</div> <div class="source_text">Permission granted by Delix Therapeutics</div> <div class="clearfix"> </div> </figcaption> </figure> <p>"The psychedelic medicine space has evolved significantly over the past decade. Next year will see both late-stage data being disclosed from well-designed studies and the potential approval of first-generation psychedelics. A highlight will be Compass Pathways’ phase 3 top-line data on a psilocybin-based therapy for treatment-resistant depression, expected in the second quarter. Third or final generation molecules, known as neuroplastogens, are also emerging as a new frontier for neuropsychiatric conditions with a focus on producing rapid impact without hallucinogenic effects. Delix Therapeutics, for instance, plans to release phase 1b data for DLX-001, a novel neuroplastogen to treat major depressive disorder, in 2025, which will inform phase 2 trials.”<br/> <em>Mark Rus, CEO, Delix Therapeutics</em></p><div class="show-small hide-large" id="mobile-inline-signup"></div><section class="storylines-carousel-wrapper hide-small show-large" id="desktop-carousel"></section> <h3 class="standard-heading">Clinical trial changes</h3> <p><strong>Research risk will be reframed</strong></p> <figure class="image-right inside_story"> <div class="figure_content"> <div><img alt="Andy Cooper" data-imagemodel="172741" src="https://imgproxy.divecdn.com/w_3_WPA7Zg8wgdjXQrZbkke9sKZI5K-eXQk-MucC0iA/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9BbmR5X0Nvb3Blcl9DRU9fQ2x1ZVBvaW50cy5qcGc=.webp"/></div> </div> <figcaption class="inside_story_caption"> <div class="caption_text">Optional Caption</div> <div class="source_text">Permission granted by CluePoints</div> <div class="clearfix"> </div> </figcaption> </figure> <p>“In the next 12 months, the concept of risk will become the central factor in all clinical trial business decisions. However, this risk will be reframed as a key component of the ‘Probability of Technical and Regulatory Success.’ As the industry increasingly adopts a data science mindset, the focus will shift from ‘what if we do?’ to ‘what if we don’t?’ scenarios. The consequences of inaction — such as failure to recruit the right sites, treat the right patients or provide proper oversight — will spark a technology-driven, industry-wide revolution. Fueled by global uncertainties, the demand for success will outweigh the fear of failure.”<br/> <em>Andy Cooper, CEO, CluePoints</em></p> <p><strong>External control arms will gain traction</strong></p> <figure class="image-right inside_story"> <div class="figure_content"> <div><img alt="Sujay Jadhav headshot" data-imagemodel="124926" src="https://imgproxy.divecdn.com/k4-jt3rREJRmIKUXEsnC0jwIvIMx4bardRHQSluiJb8/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9ZaVBfSmFkaGF2X1N1amF5X01CRTRjYWkuanBn.webp"/></div> </div> <figcaption class="inside_story_caption"> <div class="caption_text">Optional Caption</div> <div class="source_text">Permission granted by Verana Health</div> <div class="clearfix"> </div> </figcaption> </figure> <p>“In 2025, external control arms are expected to gain broader acceptance in clinical research, thanks to their ability to leverage real-world data from reliable sources such as electronic health records. This approach can help address significant ethical dilemmas in controlled trials where patients are randomized to placebo, even when effective treatments already exist; and in rare diseases, where there are often no or few treatment options available. In rare diseases, where there are smaller patient populations, ECAs allow researchers to utilize existing data, rather than finding enough patients to enroll.”<br/> <em>Sujay Jadhav, CEO, Verana Health</em></p> <p><strong>Emerging tools will streamline rare disease trials</strong></p> <figure class="image-right inside_story"> <div class="figure_content"> <div><img alt="Kiran Nistala" data-imagemodel="172742" src="https://imgproxy.divecdn.com/t7KQE-ZYc9L4wt46ECaJZzA-bMzKqcjeTL7LcNgiwOI/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9LaXJhbl9OaXN0YWxhXy5qcGc=.webp"/></div> </div> <figcaption class="inside_story_caption"> <div class="caption_text">Optional Caption</div> <div class="source_text">Permission granted by Zura Bio</div> <div class="clearfix"> </div> </figcaption> </figure> <p>“In 2025, the rare disease space will see clinical trials increasingly embracing adaptive designs and decentralized models to address the challenges of small, geographically dispersed patient populations. Advances in genetic and biomarker-driven patient stratification will enhance trial efficiency and precision, enabling faster identification of eligible participants. The integration of real-world evidence and digital health tools, such as remote monitoring and wearable devices, will make trials more accessible while reducing the burden on patients.”<br/> <em>Kiran Nistala, CMO, head of development, Zura Bio</em></p> <p><strong>Biomarkers will aid recruitment</strong></p> <figure class="image-right inside_story"> <div class="figure_content"> <div><img alt="Jim Doherty," data-imagemodel="172743" src="https://imgproxy.divecdn.com/kmCdl-lueXiFn2Uk7D81ZHJVcRTSGfyaFPg-Ng1YR6A/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9TY3JlZW5zaG90XzIwMjUtMDEtMDlfYXRfMS4wMi4yNF9QTS5wbmc=.webp"/></div> </div> <figcaption class="inside_story_caption"> <div class="caption_text">Optional Caption</div> <div class="source_text">Permission granted by Acumen Pharmaceuticals</div> <div class="clearfix"> </div> </figcaption> </figure> <p>“In 2025, we anticipate significant strides in clinical trial innovation aimed at reducing burdens on both clinical sites and participants. By leveraging advanced biomarker technologies, these innovations can enhance the precision and efficiency of clinical trial recruitment. For example, in Alzheimer's disease, biomarkers such as pTau217 can enhance trial efficiency and precision while lessening reliance on invasive procedures such as amyloid PET scans and lumbar punctures. This not only alleviates physical and emotional stress for participants but also streamlines the workload for trial sites.”<br/> <em>Jim Doherty, chief development officer, president, Acumen Pharmaceuticals</em></p> <p><strong>The industry’s site landscape could — and should — change</strong></p> <figure class="image-right inside_story"> <div class="figure_content"> <div><img alt="Karen McIntyre" data-imagemodel="172744" src="https://imgproxy.divecdn.com/SobViweup-kPOARnvVYCx16V5OClj4UZKkOrpo_nNK8/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9LYXJlbl9NY0ludHlyZS5qcGc=.webp"/></div> </div> <figcaption class="inside_story_caption"> <div class="caption_text">Optional Caption</div> <div class="source_text">Permission granted by Parexel</div> <div class="clearfix"> </div> </figcaption> </figure> <p>“The industry is trending towards there being more trials than there are sites to support them. There is no shortage of physicians who want to be involved in research but sponsors often look for sites with at least two years of demonstrated experience. However, a physician who doesn’t have much experience in commercial research may still be surrounded by teams who do. In 2025, sponsors should give new sites an opportunity to participate in studies. In addition, the industry is still treating networks like individual sites, and to maximize their benefit, they must be treated like a network with one single contract. We're going to see more movement in the site space with acquisitions and mergers — networks merging with other networks and dedicated research sites being acquired by larger networks or larger sites.”<br/> <em>Karen McIntyre, vice president, global site alliances, launch excellence, Parexel</em></p> <p><strong>The trial innovation boom will continue</strong></p> <figure class="image-right inside_story"> <div class="figure_content"> <div><img alt="Professional photo of Bari Kowal" data-imagemodel="142191" src="https://imgproxy.divecdn.com/uS9XHpUWwkN7M4DwVZHWAbUSxzzGoGba_gaS7EMw-8w/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9Lb3dhbF9CYXJpLmpwZw==.webp"/></div> </div> <figcaption class="inside_story_caption"> <div class="caption_text">Optional Caption</div> <div class="source_text">Permission granted by Bari Kowal</div> <div class="clearfix"> </div> </figcaption> </figure> <p><span><span><span><span>“In 2025, our industry will continue to see a boom in clinical trial innovation. Over the last several years, we’ve seen an explosion of potential therapies, providing a tremendous opportunity to offer new medicines to patients in need. With this opportunity comes the challenge of executing clinical trials as efficiently as possible. Utilizing technologies like digital biomarkers, advancing health data interoperability, and applying AI and machine learning to improve efficiencies can dramatically improve clinical trial execution. Such technologies enable a deeper understanding of diseases, more precise measurement of treatment effects, a more inclusive approach to patient participation, and the ability to assess vast amounts of data. As we continue to explore and integrate these technologies into our clinical research, we are entering a new era of drug development.”</span></span></span></span><br/> <span><span><em><span><span>Bari Kowal, senior vice president, development operations and portfolio management, Regeneron </span></span></em></span></span></p> <p><strong>The need for novel endpoints will grow</strong></p> <figure class="image-right inside_story"> <div class="figure_content"> <div><img alt="Faye Feller" data-imagemodel="166339" src="https://imgproxy.divecdn.com/ew6deeJVjA8a0E7UWWON1FZd0NWtm8PLdEIaIthZQtE/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9mYXllZmVsbGVyX1BWMTAwXzIwMjQuanBn.webp"/></div> </div> <figcaption class="inside_story_caption"> <div class="caption_text">Optional Caption</div> <div class="source_text">Permission granted by Geron</div> <div class="clearfix"> </div> </figcaption> </figure> <p><span><span><span><span>“There is a growing need for novel endpoints that move the goal post to more impactfully improve patient outcomes by better highlighting the clinical benefits of the innovative treatments our industry is developing. Endpoints should not only measure the clinical benefits that patients and doctors deem important but should be tied to the mechanism of a medicine. It is critical to bring all involved groups including regulatory authorities, patient advocates, investigators and key opinion leaders, into the room earlier for R&D so that alignment on the clinical development pathway is achieved from the very beginning. Otherwise, we risk a medicine failing if we simply continue to follow precedent when bringing new treatments.” </span></span></span></span><br/> <em><span><span><span>Dr. Faye Feller, executive vice president, chief medical officer, Geron</span></span></span></em></p> <p><strong>SPAs could aid late-stage trials</strong></p> <figure class="image-right inside_story"> <div class="figure_content"> <div><img alt="Pravin Dugel" data-imagemodel="172746" src="https://imgproxy.divecdn.com/Lz32hHevPi80DH-84FMxJWpyrYz2Wsy4_rSxaTzdasE/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9QcmF2aW5fNDAwWDQwMC5wbmc=.webp"/></div> </div> <figcaption class="inside_story_caption"> <div class="caption_text">Optional Caption</div> <div class="source_text">Permission granted by Ocular Therapeutix</div> <div class="clearfix"> </div> </figcaption> </figure> <p>"Much has been written about uncertainty surrounding the upcoming changes to leadership within the FDA and HHS. As a possible response to this, we may see increasing collaboration between sponsors and the FDA on late-stage R&D programs through efforts like the special protocol assessment process. By working directly with the FDA and maintaining an ongoing dialogue on trial design, the validity of evidence, endpoints and their analysis, sponsors can get critical buy-in via SPAs, or other collaborative measures, that can help de-risk late-stage development and increase confidence in their pivotal stage programs. Medicine is an inherently bipartisan endeavor, and SPAs can play a fundamental role in maintaining the pace of biomedical innovation."<br/> <em>Dr. Pravin Dugel, CEO, president, chairman, Ocular Therapeutix</em></p> <p><strong>Pharmas will need to address costs, payments and data</strong></p> <figure class="image-right inside_story"> <div class="figure_content"> <div><img alt="Zahiah Gueddar" data-imagemodel="172747" src="https://imgproxy.divecdn.com/rKZ-tHhVYTPALdqlJXAsqyitSq4bsINz3l_Vn4J6GQg/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9aZWVfWmVlX0d1ZWRkYXIucG5n.webp"/></div> </div> <figcaption class="inside_story_caption"> <div class="caption_text">Optional Caption</div> <div class="source_text">Permission granted by IQVIA</div> <div class="clearfix"> </div> </figcaption> </figure> <p>“As the clinical trials landscape evolves, several key trends will shape the sector in 2025. Cost management will remain a top priority. To reduce dropout rates, sponsors will work to address grant spending, which currently accounts for about 50% of trial budgets. Improving the financial management will require improved forecasting and transparency from start to finish.</p> <div class="hybrid-ad-wrapper hide-small show-large"> <div class="hybrid-ad-inner-wrapper"> <div class="hide-small show-large"> <div data-container-ad-unit-id="/21662595662/pharmavoice/pharmavoicehybrid4-desktop"></div> <div id="dfp-hybrid4-desktop"> <script> waitToLoadAds.push(function() { googletag.cmd.push(function() { if (window.dfp_visibility == 'desktop' ) { googletag.display('dfp-hybrid4-desktop'); googletag.pubads().addEventListener('slotRenderEnded', function (event) { var adUnitPath = '/21662595662/pharmavoice/pharmavoicehybrid4'; var onProformative = false; if (onProformative && event.slot.getAdUnitPath() === adUnitPath && !event.isEmpty ) { var adUnitPathWithVisibility = adUnitPath + '-desktop'; var selector = '.pf-comments__ad-wrapper [data-container-ad-unit-id="' + adUnitPathWithVisibility + '"]'; if (!$(selector).closest('.pf-comments__ad-wrapper').hasClass('borders')) { $(selector).closest('.pf-comments__ad-wrapper').addClass('borders') } } }); } }); }); </script> </div> </div> </div> </div> <section class="storylines-carousel-wrapper show-small hide-large" id="mobile-carousel"></section> <p>Sites and sponsors will also increasingly address challenges associated with participant reimbursement. The industry is realizing that delayed and static payment options foster challenges in enrollment and retention. Organizations realize they will need more flexible and timely payment processes to improve outcomes.</p> <p>With the expansion of clinical trial technology, sites and sponsors will also prioritize data ownership, especially as regulations and guidelines relating to data privacy and security increase across the globe.” <br/> <em>Zahiah Gueddar, senior director, commercial, IQVIA </em></p> <h3 class="standard-heading">Potential policy and commercialization shifts</h3> <p><strong>The IRA will create challenges in drug development</strong></p> <figure class="image-right inside_story"> <div class="figure_content"> <div><img data-imagemodel="-1" src="https://imgproxy.divecdn.com/zhV7w3FSzwfcYyM4foFRes8UL7c07iuncCa1HfJuKAs/raw:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9BcmllbF9LYXR6X2hlYWRzaG90LmpwZWc="/></div> <div> </div> </div> <figcaption class="inside_story_caption"> <div class="caption_text">Optional Caption</div> <div class="source_text">Permission granted by H1</div> <div class="clearfix"> </div> </figcaption> </figure> <p>“We will begin to feel the unintended consequences of the Inflation Reduction Act in the coming year, and it will significantly change the landscape of clinical trials and drug development as we know it. As pharma companies shift their focus toward fewer, high-value therapeutic areas in light of the IRA’s drug price negotiations, the overall number of clinical trials will go down. Additionally, we’ll see a move to multi-indication trials to maximize profitability. While this approach aims to improve ROI before potential price controls kick in, it complicates trial design and recruitment, increasing the time it takes to get treatments to market.”<br/> <em>Ariel Katz, CEO, co-founder, H1</em></p> <p><strong>Congress could impact rare disease R&D</strong></p> <figure class="image-right inside_story"> <div class="figure_content"> <div><img alt="Stacey Frisk" data-imagemodel="172748" src="https://imgproxy.divecdn.com/OCwJgQ85cXlRHTmLkQyzZ-dGupI6jpfNA3LX1ihOe0k/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9TdGFjZXlGcmlza2hlYWRzaG90LmpwZw==.webp"/></div> </div> <figcaption class="inside_story_caption"> <div class="caption_text">Optional Caption</div> <div class="source_text">Permission granted by Rare Disease Company Coalition</div> <div class="clearfix"> </div> </figcaption> </figure> <p>“With key provisions of the Tax Cuts and Jobs Act set to expire this year, the upcoming tax debate in Congress will have significant implications for the rare disease community. Lawmakers have an opportunity to restore the Orphan Drug Tax Credit — an important incentive for companies working on rare disease treatments — to its historic 50% level. The opportunities for innovation in 2025 and beyond are enormous, but there is more Congress can do to defray the significant financial cost and risk that comes R&D for small patient populations.”<br/> <em>Stacey Frisk, executive director, Rare Disease Company Coalition</em></p> <p><strong>Coverage for obesity will expand</strong></p> <figure class="image-right inside_story"> <div class="figure_content"> <div><img alt="George Hampton" data-imagemodel="172749" src="https://imgproxy.divecdn.com/oc4XeqOMrQqbtrtxGx29dp_FZw59I9x7BMXJw4gHz4Q/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9TY3JlZW5zaG90XzIwMjUtMDEtMDlfYXRfMS4xOC40OF9QTS5wbmc=.webp"/></div> </div> <figcaption class="inside_story_caption"> <div class="caption_text">Optional Caption</div> <div class="source_text">Permission granted by Currax Pharmaceuticals</div> <div class="clearfix"> </div> </figcaption> </figure> <p>“We see a turning point in 2025 with insurance coverage for obesity care becoming reality. Leading advocacy groups and legislative champions are driving the passage of the Treat and Reduce Obesity Act, which is currently making its way through key congressional committees. I've made several trips to Washington over the past year to talk with legislators, and the bill has bipartisan support. Congress now has everything it needs, including Congressional Budget Office guidance, to make this a reality for patients and their families. Enacting this law marks the beginning of a new era, where patients with obesity are finally treated with the urgency and respect they deserve.”<br/> <em>George Hampton, CEO, president, Currax Pharmaceuticals</em></p> <p><strong>Manufacturing costs could rise</strong></p> <figure class="image-right inside_story"> <div class="figure_content"> <div><img data-imagemodel="-1" src="https://imgproxy.divecdn.com/2vg0QJI51hlOoDxVypCDnq_-sRPK4BikSYJx594sXUU/raw:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9TcGVjdG9yX0lyYV9ONEVyeUVzLmpwZw=="/></div> </div> <figcaption class="inside_story_caption"> <div class="caption_text">Optional Caption</div> <div class="source_text">Image Source</div> <div class="clearfix"> </div> </figcaption> </figure> <p>“My biggest concern for 2025 is the difficulty in sourcing active pharmaceutical ingredients for clinical trials. With the Novo-Catalent deal taking out some capacity in the CDMO space, the Biosecure Act impacting WuXi Bio as a supplier and the specter of tariffs already causing increases in clinical supplies costs from Canada and potentially China, I predict manufacturing costs for both clinical supplies and finished pharmaceutical goods will come under significant pressure in 2025. This may raise the cost of clinical trials and new drugs even higher.”<br/> <em>Ira Spector, CEO, SFA Therapeutics</em></p> <p><strong>New cell and gene therapies will expand care</strong></p> <figure class="image-right inside_story"> <div class="figure_content"> <div><img alt="Joe DePinto" data-imagemodel="167142" src="https://imgproxy.divecdn.com/drbEJRNIpWcN1LHl3TjskH4LhIrWCKjDXg8vOwY4uQE/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9EZVBpbnRvX0pvZV9QVjEwMF8yMDI0LmpwZWc=.webp"/></div> </div> <figcaption class="inside_story_caption"> <div class="caption_text">Optional Caption</div> <div class="source_text">Permission granted by McKesson</div> <div class="clearfix"> </div> </figcaption> </figure> <p>“We’re on the cusp of a transformative moment in cell and gene therapy as we prepare for the next wave to come to market. One of the key trends in 2025 will be the transition of care from academic centers to community settings. The recent FDA approvals of two autologous solid tumor cell therapies, Iovance Biotherapeutics' Amtagvi and Adaptimmune’s Tecelra, will serve as a catalyst for this shift. As more solid tumor CGTs become available, academic centers will face growing capacity challenges, and patients and providers will increasingly want to access these innovative therapies close to home. At the same time, allogeneic cell therapies are also gaining traction, and Pierre Fabre Pharmaceuticals’ allogeneic T-cell immunotherapy, which has a PDUFA date in April 2025, could be the first in a new wave of medicines that use cells from donor patients to streamline manufacturing and drive broader accessibility of CGTs.”<br/> <em>Joe DePinto, head, cell, gene and advanced therapies, McKesson</em></p> <p><strong>More rare disease companies will launch their own products</strong></p> <figure class="image-right inside_story"> <div class="figure_content"> <div><img alt="R. Nolan Townsend" data-imagemodel="172750" src="https://imgproxy.divecdn.com/5jqRKp8-h7scxs9IyMBToQb43XCos0GntKmsjRx5J0g/g:ce/rs:fit:1600:0/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9Ob2xhbl9Ub3duc2VuZF8wMDIuanBn.webp"/></div> </div> <figcaption class="inside_story_caption"> <div class="caption_text">Optional Caption</div> <div class="source_text">Permission granted by Lexeo Therapeutics</div> <div class="clearfix"> </div> </figcaption> </figure> <p>“In 2025, we will see more biotech companies independently commercializing their own products. The potential revenues from a category like rare disease would represent a challenge to ‘move the needle’ on a pharma revenue line constructed of common population products, raising the bar for pharma interest in rare disease. In this context, the unmet need in rare disease persists and the profitability profile of a category that requires smaller registrational studies, with a faster path to approval and modest commercial infrastructure remains. Biotech companies are now in a unique setup to lead the way commercially in rare disease, and we are seeing an increasing number of definitive commercial success stories in these rare diseases, with many more to come.”<br/> <em>R. Nolan Townsend, CEO, Lexeo Therapeutics</em></p> </div> <div class="reading-list recommended-reading"> <h3 class="sidebar-box__header reading-list__header">Recommended Reading</h3> <ul class="list-no-bullets"> <li class="reading-list__item"> <a href="https://www.pharmavoice.com/news/pharma-preview-2025-prediction-ai-drug-discovery/736470/" target="_blank" class="reading-list__link analytics t-article-end-recommended"> PharmaVoice’s Crystal Ball: The industry’s AI future </a> <span class="label label--soft"> <img src="/static/img/offsite_black.png?102717100918" class="off-site-link" alt="offsite link" width="12" height="12" /> <span>Meagan Parrish</span> </span> </li> <li class="reading-list__item"> <a href="https://www.pharmavoice.com/news/approvals-to-watch-2025-pdufa-fda-pharma-drug/736479/" target="_blank" class="reading-list__link analytics t-article-end-recommended"> 4 closely watched FDA approval dates in 2025 from J&J, Novo and more </a> <span class="label label--soft"> <img src="/static/img/offsite_black.png?102717100918" class="off-site-link" alt="offsite link" width="12" height="12" /> <span>Alexandra Pecci</span> </span> </li> </ul> </div> <div class="post-article-wrapper"> <div class="share-buttons"> <ul class="social-button-list"> <li> <a href="http://www.linkedin.com/shareArticle?mini=true&url=https%3A//www.pharmavoice.com/news/pharma-crystal-ball-2025-rd-policy-innovation-drug-clinical/736935/&title=PharmaVoice%E2%80%99s%20Crystal%20Ball%3A%20Industry%20shifts%20in%20R%26D%2C%20policy%20and%20clinical%20trials" class="social-button analytics t-article-end-social-linkedin" title="Post"> <img src="/static/img/social_icons/article_page/linkedin.svg?092716141024" alt="Post to LinkedIn"> </a> </li> <li> <a href="https://www.facebook.com/sharer/sharer.php?u=https%3A//www.pharmavoice.com/news/pharma-crystal-ball-2025-rd-policy-innovation-drug-clinical/736935/" class="social-button analytics t-article-end-social-facebook" title="Share"> <img src="/static/img/social_icons/article_page/facebook.svg?440116200824" alt="Share on Facebook"> </a> </li> <li> <a href="https://twitter.com/intent/tweet?text=PharmaVoice%E2%80%99s%20Crystal%20Ball%3A%20Industry%20shifts%20in%20R%26D%2C%20policy%20and%20clinical%20trials%20https%3A//www.pharmavoice.com/news/pharma-crystal-ball-2025-rd-policy-innovation-drug-clinical/736935/%20via%20@PharmaVoice" class="social-button analytics t-article-end-social-twitter" title="Post"> <img src="/static/img/social_icons/article_page/x.svg?092716141024" alt="Post to X"> </a> </li> <li> <a href="javascript:window.print()" class="social-button js-social-button-print" title="Print"> <img src="/static/img/social_icons/article_page/print.svg?440116200824" alt="Print this page"> </a> </li> <li> <a href="/cdn-cgi/l/email-protection#cbf498bea9a1aea8bff69ba3aab9a6aa9da4a2a8aeee8ef9eef3fbeef2f2b8eef9fb88b9b2b8bfaaa7eef9fb89aaa7a7eef88aeef9fb82a5afbeb8bfb9b2eef9fbb8a3a2adbfb8eef9fba2a5eef9fb99eef9fd8feef988eef9fbbba4a7a2a8b2eef9fbaaa5afeef9fba8a7a2a5a2a8aaa7eef9fbbfb9a2aaa7b8edaaa6bbf089a4afb2f6a3bfbfbbb8eef88ae4e4bcbcbce5bba3aab9a6aabda4a2a8aee5a8a4a6e4a5aebcb8e4bba3aab9a6aae6a8b9b2b8bfaaa7e6a9aaa7a7e6f9fbf9fee6b9afe6bba4a7a2a8b2e6a2a5a5a4bdaabfa2a4a5e6afb9beace6a8a7a2a5a2a8aaa7e4fcf8fdf2f8fee4" class="social-button analytics t-article-end-social-email" title="Email"> <img src="/static/img/social_icons/article_page/email.svg?092716141024" alt="Email this page"> </a> </li> </ul> </div> <div class="post-article-topics"> <div> <span>Filed Under:</span> <span><a class="topic analytics t-article-end-topic" href="/topic/biotech/">Biotech, </a></span> <span><a class="topic analytics t-article-end-topic" href="/topic/commercialization/">Commercialization, </a></span> <span><a class="topic analytics t-article-end-topic" href="/topic/leadership/">Leadership, </a></span> <span><a class="topic analytics t-article-end-topic" href="/topic/patient/">Patient, </a></span> <span><a class="topic analytics t-article-end-topic" href="/topic/pharma/">Pharma, </a></span> <span><a class="topic analytics t-article-end-topic" href="/topic/policy-regulation/">Policy & Regulation, </a></span> <span><a class="topic analytics t-article-end-topic" href="/topic/research-development/">Research & Development</a></span> </div> </div> </div> </div> </div> </div> </article> <div id="newspost_overlay" style="display: none"></div> <form id="content_gate_signup" class="js-form-email-validate" name="signup" style="display: none"> <h3>Continue reading for free</h3> <label id="subtitle">Sign up for our daily newsletter to access this article.</label> <p style="display: none" class="signup-form-error-message form-error__message padding-left">YOU MUST AGREE TO OUR TERMS OF USE AND PRIVACY POLICY.</p> <div id="input-container" class="email-input js-email-input"> <div id="input-box-and-button"> <input id="content_gate_input" type="email" placeholder="Work email address" required> <div id="content_gate_button"> <button class="button button--medium">Read now</button> </div> </div> </div> <p class="email-check js-already-subscriber-prompt padding-left">Already a subscriber? Sign in with your email above.</p> <ul style="display: none" class="signup-list list-no-bullets padding-left inline-gate-signup"> <li> <input type="checkbox" name="user_consent" id="id_user_consent-gate" value="1" class="checkbox"/> <label for="id_user_consent-gate"> <span class="signup-user-consent_box"> <span> By signing up to receive our newsletter, you agree to our <a href="https://www.techtarget.com/terms-of-use/" target="_blank">Terms of Use</a> and <a href="https://www.techtarget.com/privacy-policy/" target="_blank">Privacy Policy</a>. You can unsubscribe at anytime. </span> </span> </label> </li> </ul> <label style="display: none" id="confirmation">All set! You'll get a confirmation email from us shortly.</label> </form> <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script> window.siteName = 'PharmaVoice'; window.designType = 'standard'; window.cssClass = '.article-body'; window.previewGatePage = ''; window.showGatePreview = ''; </script> <script type="module" src="/static/js/dist/editorialGate.bundle.js?325815190225" ></script> <section class="signup call-out elevated-footer standard-newspost-mobile show-small show-medium hide-large"> <div class="row"> <div class="large-11 medium-11 medium-centered columns footer-signup" style="display: flex"> <div class="footer-signup__content"> <h3>PharmaVoice stories and insights delivered to your inbox</h3> <p class="subhead">Get the free daily newsletter read by industry leaders</p> <form class="form js-form-email-validate" name="signup" action="/signup/" method="POST"> <label for="id_176d60_email" class="email-input js-email-input"> <span class="screen-reader-text">Email:</span> <input type="email" name="email" placeholder="Work email address" class="email" required id="id_176d60_email"> </label> <input type="hidden" name="signup_box_location" value="elevated_footer"> <input type="hidden" name="signup_initial_url_path" value="/news/pharma-crystal-ball-2025-rd-policy-innovation-drug-clinical/736935/"> <input type="hidden" name="signup_internal_referrer"> <input type="hidden" name="signup_external_referrer"> <input type="hidden" name="referral_url"> <input type="hidden" name="js_enabled" value="0" id="id_176d60_js_enabled"> <ul class="signup-list list-no-bullets"> <li> <label><span class="screen-reader-text">Select user consent:</span></label> <input type="checkbox" name="user_consent" id="id_user_consent-elevated_footer" value="1" class="checkbox"/> <label for="id_user_consent-elevated_footer"> <span class="signup-user-consent_box"> <span> By signing up to receive our newsletter, you agree to our <a href="https://www.techtarget.com/terms-of-use/" target="_blank">Terms of Use</a> and <a href="https://www.techtarget.com/privacy-policy/" target="_blank">Privacy Policy</a>. You can unsubscribe at anytime. </span> </span> </label> </li> </ul> <button class="button button--medium signup-button" type="submit" value="Sign up">Sign up</button> <script type="module" src="/static/js/dist/sendEmailToLytics.bundle.js?325815190225" ></script> <label class="error email_error" style="display:none;">A valid email address is required.</label> <label class="error newsletter-error" style="display:none;">Please select at least one newsletter.</label> </form> </div> <div class="footer-signup__image"> <img class="desktop-image" src="/static/img/pharmavoice/signup-article.png?080016020822" width="275" height="275" loading="lazy" alt="PharmaVoice newsletter example"> </div> </div> </div> </section> <div class="sidebar-box hide-large editors-pick-footer-mobile"> <h3 class="sidebar-box__header"> Editors' pick </h3> <ul class="feed"> <li class="row feed__item"> <div class="medium-5 columns"> <figure class="feed__image-container"> <a class="feed__image analytics t-edfooter-edpicks-1" href="/news/vaccine-makers-earnings-report-flu-rsv-moderna-pfizer-sanofi/740290/"> <img class="" src="https://imgproxy.divecdn.com/7F8wEuhfI0fNaqc2RDTt3t4MpPMWyzoaTSyYGk58m-4/g:nowe:0:553/c:4958:2801/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMDg0MDA2MjYwLmpwZw==.webp" width="1200" height="675" srcset="https://imgproxy.divecdn.com/cz1XQZZMZMEj8QdPgPZFyBVLQBjPNvjZM54KnEIbgyA/g:nowe:0:553/c:4958:2801/rs:fill:300:169:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMDg0MDA2MjYwLmpwZw==.webp 300w, https://imgproxy.divecdn.com/DE1VoMjZwQUnWWMg4MvDi-y5neA9xvoCJs5ghNI1Ocg/g:nowe:0:553/c:4958:2801/rs:fill:600:338:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMDg0MDA2MjYwLmpwZw==.webp 600w, https://imgproxy.divecdn.com/7F8wEuhfI0fNaqc2RDTt3t4MpPMWyzoaTSyYGk58m-4/g:nowe:0:553/c:4958:2801/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMDg0MDA2MjYwLmpwZw==.webp 1200w" sizes="(min-width: 40em ) 25vw, 100vw" alt="Pfizer CEO Albert Bourla" loading="lazy" > </a> <figcaption> <img class="feed__attribution-icon" src="/static/images/info-icon.png?234917240220" width="16" height="16" alt="Image attribution tooltip" tabindex="0"> <div class="feed__attribution">Drew Angerer via Getty Images</div> <img class="feed__attribution-icon" src="/static/images/info-icon.png?234917240220" width="16" height="16" alt="Image attribution tooltip" tabindex="-1"> </figcaption> </figure> </div> <div class="medium-7 columns"> <h3 class="feed__title feed__title--display"> <a href="/news/vaccine-makers-earnings-report-flu-rsv-moderna-pfizer-sanofi/740290/" class="analytics t-edfooter-edpicks-1"> Challenges mount for vaccine makers </a> </h3> <p class="feed__description hide-small show-large">End-of-year earnings reports reveal drugmakers are grappling with declining vaccination rates and an unpredictable Trump administration.</p> <div class="secondary-label"> By Amy Baxter • <span class="secondary-label">Feb. 19, 2025</span> </div> </div> </li> </ul> </div> <div style="display: none;" id="inline-signup-html-desktop"> <div class="inline-signup"> <p class="inline-signup__copy">Keep up with the story. Subscribe to the PharmaVoice free daily newsletter</p> <form class="form js-form-email-validate" name="signup" action="/signup/" method="POST"> <label for="id_be7265_email" class="email-input js-email-input"> <span class="screen-reader-text">Email:</span> <input type="email" name="email" placeholder="Work email address" class="email" required id="id_be7265_email"> </label> <input type="hidden" name="signup_box_location" value="inline"> <input type="hidden" name="signup_initial_url_path" value="/news/pharma-crystal-ball-2025-rd-policy-innovation-drug-clinical/736935/"> <input type="hidden" name="signup_internal_referrer"> <input type="hidden" name="signup_external_referrer"> <input type="hidden" name="referral_url"> <input type="hidden" name="js_enabled" value="0" id="id_be7265_js_enabled"> <ul class="signup-list list-no-bullets"> <li> <label><span class="screen-reader-text">Select user consent:</span></label> <input type="checkbox" name="user_consent" id="id_user_consent-inline" value="1" class="checkbox"/> <label for="id_user_consent-inline"> <span class="signup-user-consent_box"> <span> By signing up to receive our newsletter, you agree to our <a href="https://www.techtarget.com/terms-of-use/" target="_blank">Terms of Use</a> and <a href="https://www.techtarget.com/privacy-policy/" target="_blank">Privacy Policy</a>. You can unsubscribe at anytime. </span> </span> </label> </li> </ul> <button class="button button--medium signup-button" type="submit" value="Sign up">Sign up</button> <script type="module" src="/static/js/dist/sendEmailToLytics.bundle.js?325815190225" ></script> <label class="error email_error" style="display:none;">A valid email address is required.</label> <label class="error newsletter-error" style="display:none;">Please select at least one newsletter.</label> </form> </div> <div class="subscriber-demographics demographics-form" id="demographics-box-inline"></div> <script src="/static/js/subscriberDemographicsForm.js?450216090125"></script> <script> var siteName = 'PharmaVoice' || null; if (siteName) { setupFormCallbackAndCreateFormIfSub(siteName, 'inline'); } </script> </div> <script type="text/javascript"> $(document).ready(function () { // copy the contents of the generic_signup partial into the desktop_signup_spot $desktop_signup_spot = $("#desktop-inline-signup"); $desktop_signup = $("#inline-signup-html-desktop").children(); $desktop_signup_spot.append($desktop_signup); $("#inline-signup-html-desktop").remove(); }); </script> <link rel="preload" href="https://d12v9rtnomnebu.cloudfront.net/carousel/glider.min.css" as="style" onload="this.onload=null;this.rel='stylesheet'">  <div style="display: none" id="carousel_images"> <div class="proximized_carousel_image" id="carousel_0"> <img class="carousel-item__image" src="https://imgproxy.divecdn.com/QH-Fd_YROaSp-E2Ck3ieCULDDSkcbYru4KedWX0f19I/g:ce/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNzY4MjQ1NDU1LmpwZw==.webp" width="1200" height="675" srcset="https://imgproxy.divecdn.com/1TQ0Vg_-x5x2Jf0klZ_0KUVQjAm2f9yaYK_Szk6PZ90/g:ce/rs:fill:300:169:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNzY4MjQ1NDU1LmpwZw==.webp 300w, https://imgproxy.divecdn.com/A74IWXhL8VWjScuicZ99cy7AcK4ZLH60m4E7lS5ToOw/g:ce/rs:fill:600:338:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNzY4MjQ1NDU1LmpwZw==.webp 600w, https://imgproxy.divecdn.com/QH-Fd_YROaSp-E2Ck3ieCULDDSkcbYru4KedWX0f19I/g:ce/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNzY4MjQ1NDU1LmpwZw==.webp 1200w" sizes="(min-width: 40em ) 25vw, 100vw" alt="2024 market" > </div> <div class="proximized_carousel_image" id="carousel_1"> <img class="carousel-item__image" src="https://imgproxy.divecdn.com/sXpLh8PW_u4d8qu8W0BfVmZ_4izWQKbdf8wpR2pzUjQ/g:ce/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNjg0NzMwOTg5LmpwZw==.webp" width="1200" height="675" srcset="https://imgproxy.divecdn.com/YcJVBg6iu1lWOf-zG5s3sASnOEzQiNy8zjeIQC5FO-I/g:ce/rs:fill:300:169:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNjg0NzMwOTg5LmpwZw==.webp 300w, https://imgproxy.divecdn.com/CsMK0L5Zi4W1J1k7sqq1tDXeb_Tpb0sKvdeilv7CmRo/g:ce/rs:fill:600:338:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNjg0NzMwOTg5LmpwZw==.webp 600w, https://imgproxy.divecdn.com/sXpLh8PW_u4d8qu8W0BfVmZ_4izWQKbdf8wpR2pzUjQ/g:ce/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNjg0NzMwOTg5LmpwZw==.webp 1200w" sizes="(min-width: 40em ) 25vw, 100vw" alt="2024 Crystal Ball Trials" > </div> <div class="proximized_carousel_image" id="carousel_2"> <img class="carousel-item__image" src="https://imgproxy.divecdn.com/cQb-J2xurJHyOdPP8WvyATLsi4qyw9eVsqT9sWfuWcg/g:ce/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTczMjE1OTU5LmpwZw==.webp" width="1200" height="675" srcset="https://imgproxy.divecdn.com/LN-ssiYGsdcMA-XMlZqKZ051aEslUXtOcD0Ii5f2InQ/g:ce/rs:fill:300:169:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTczMjE1OTU5LmpwZw==.webp 300w, https://imgproxy.divecdn.com/dAoFjTwZqeVIhr8lajl4wnet4ka_JgcArCNaE9gtf3s/g:ce/rs:fill:600:338:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTczMjE1OTU5LmpwZw==.webp 600w, https://imgproxy.divecdn.com/cQb-J2xurJHyOdPP8WvyATLsi4qyw9eVsqT9sWfuWcg/g:ce/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTczMjE1OTU5LmpwZw==.webp 1200w" sizes="(min-width: 40em ) 25vw, 100vw" alt="crystal ball ai 2025" > </div> <div class="proximized_carousel_image" id="carousel_3"> <img class="carousel-item__image" src="https://imgproxy.divecdn.com/uIBVzwoeE5cLnf1iRDlgiHw-Y-qbiei33eJjWwLu7r8/g:ce/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy02OTM1Mjg5NTYuanBn.webp" width="1200" height="675" srcset="https://imgproxy.divecdn.com/kOPqk2xBaHFcAKZ5StN7SrpkouxiKhzaKlrYbWiHoGs/g:ce/rs:fill:300:169:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy02OTM1Mjg5NTYuanBn.webp 300w, https://imgproxy.divecdn.com/7FVbPiBClgI4C0SymVGQ-8Kh4pLaoUvmg6Cmnc3Iwgs/g:ce/rs:fill:600:338:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy02OTM1Mjg5NTYuanBn.webp 600w, https://imgproxy.divecdn.com/uIBVzwoeE5cLnf1iRDlgiHw-Y-qbiei33eJjWwLu7r8/g:ce/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy02OTM1Mjg5NTYuanBn.webp 1200w" sizes="(min-width: 40em ) 25vw, 100vw" alt="Biopharma market" > </div> <div class="proximized_carousel_image" id="carousel_4"> <img class="carousel-item__image" src="https://imgproxy.divecdn.com/dxGYuaEeX6gdNncHPvT4jJCvkKFpeCaNm5LXGJurw9Y/g:ce/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDcyMTA3MDgwLmpwZw==.webp" width="1200" height="675" srcset="https://imgproxy.divecdn.com/-y5siHf2TyRw3WAz8FtQTSrcUl9fLNrHmyr0jGOA-yg/g:ce/rs:fill:300:169:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDcyMTA3MDgwLmpwZw==.webp 300w, https://imgproxy.divecdn.com/Ocw0TN14Bt9nAk1nRTQR7fXGIOR0SJsOIN4b_IKlZ8U/g:ce/rs:fill:600:338:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDcyMTA3MDgwLmpwZw==.webp 600w, https://imgproxy.divecdn.com/dxGYuaEeX6gdNncHPvT4jJCvkKFpeCaNm5LXGJurw9Y/g:ce/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDcyMTA3MDgwLmpwZw==.webp 1200w" sizes="(min-width: 40em ) 25vw, 100vw" alt="petri dish seeds" > </div> </div> <script src="https://d12v9rtnomnebu.cloudfront.net/carousel/glider-compat.min.js" defer></script> <script src="https://d12v9rtnomnebu.cloudfront.net/carousel/glider.min.js" defer></script> <script> window.carouselData = {}; window.carouselData.carouselStories = [{"title": "PharmaVoice\u2019s Crystal Ball: Perspectives on the financial future", "link": "https://www.pharmavoice.com/news/pharma-preview-biotech-financial-outlook/703706/", "pub_date": "Jan 09, 2024"}, {"title": "PharmaVoice\u2019s Crystal Ball: What\u2019s next in drug innovation and clinical trials", "link": "https://www.pharmavoice.com/news/pharma-outlook-trends-drug-innovation-clinical-trials/703727/", "pub_date": "Jan 11, 2024"}, {"title": "PharmaVoice\u2019s Crystal Ball: The industry\u2019s AI future", "link": "https://www.pharmavoice.com/news/pharma-preview-2025-prediction-ai-drug-discovery/736470/", "pub_date": "Jan 07, 2025"}, {"title": "Will 2025 mark pharma\u2019s pivot to bigger deals after years of lackluster M&A?", "link": "https://www.pharmavoice.com/news/pharma-dealmaking-2025-outlook/737225/", "pub_date": "Jan 14, 2025"}, {"title": "Pharma\u2019s forecast for 2025: Sowing seeds of a rebound", "link": "https://www.pharmavoice.com/news/pharma-trends-outlook-2025/738839/", "pub_date": "Jan 31, 2025"}] // For each carousel story in our object, add the HTML contents of the corresponding .proximized_carousel_image DIV as a property // This will be used in the carousel.mustache.html template to display the image for (i=0; i < $('.proximized_carousel_image').length; i++) { window.carouselData.carouselStories[i].proximizedImage = $('#carousel_' + i).html().trim(); } // Remove the DOM elements for the proximized images since we already have what we need from them $('#carousel_images').remove(); window.carouselData.preferredTopic = "Biotech" window.carouselData.preferredTopicLink = "/topic/biotech/" window.carouselData.storylineTitle = "Year in Preview" </script> <script type="module" src="/static/js/dist/storylinesCarousel.bundle.js?325815190225" ></script> </section> <aside class="sidebar large-4 columns"> <div class="hybrid-ad-wrapper hide-small show-large"> <div class="hybrid-ad-inner-wrapper"> <div class="hide-small show-large"> <div data-container-ad-unit-id="/21662595662/pharmavoice/pharmavoicehybrid1-desktop"></div> <div id='dfp-hybrid1-desktop'> <script> waitToLoadAds.push(function() { googletag.cmd.push(function() { if (window.dfp_visibility == 'desktop' ) { googletag.display('dfp-hybrid1-desktop'); googletag.pubads().addEventListener('slotRenderEnded', function (event) { var adUnitPath = '/21662595662/pharmavoice/pharmavoicehybrid1'; var onProformative = false; if (onProformative && event.slot.getAdUnitPath() === adUnitPath && !event.isEmpty ) { var adUnitPathWithVisibility = adUnitPath + '-desktop'; var selector = '.pf-comments__ad-wrapper [data-container-ad-unit-id="' + adUnitPathWithVisibility + '"]'; if (!$(selector).closest('.pf-comments__ad-wrapper').hasClass('borders')) { $(selector).closest('.pf-comments__ad-wrapper').addClass('borders') } } }); } }); }); </script> </div> </div> </div> </div> <div class="signup sidebar-signup-box hide-small show-large" data-box-priority="0"> <h3 class="sidebar-signup-box__header">Get the free newsletter</h3> <p class="sidebar-signup-box__description">Subscribe to PharmaVoice for important stories, insights & perspectives</p> <form class="form js-form-email-validate" name="signup" action="/signup/" method="POST"> <label for="id_119f83_email" class="email-input js-email-input"> <span class="screen-reader-text">Email:</span> <input type="email" name="email" placeholder="Work email address" class="email" required id="id_119f83_email"> </label> <input type="hidden" name="signup_box_location" value="sidebar"> <input type="hidden" name="signup_initial_url_path" value="/news/pharma-crystal-ball-2025-rd-policy-innovation-drug-clinical/736935/"> <input type="hidden" name="signup_internal_referrer"> <input type="hidden" name="signup_external_referrer"> <input type="hidden" name="referral_url"> <input type="hidden" name="js_enabled" value="0" id="id_119f83_js_enabled"> <ul class="signup-list list-no-bullets"> <li> <label><span class="screen-reader-text">Select user consent:</span></label> <input type="checkbox" name="user_consent" id="id_user_consent-sidebar" value="1" class="checkbox"/> <label for="id_user_consent-sidebar"> <span class="signup-user-consent_box"> <span> By signing up to receive our newsletter, you agree to our <a href="https://www.techtarget.com/terms-of-use/" target="_blank">Terms of Use</a> and <a href="https://www.techtarget.com/privacy-policy/" target="_blank">Privacy Policy</a>. You can unsubscribe at anytime. </span> </span> </label> </li> </ul> <button class="button button--medium signup-button" type="submit" value="Sign up">Sign up</button> <script type="module" src="/static/js/dist/sendEmailToLytics.bundle.js?325815190225" ></script> <label class="error email_error" style="display:none;">A valid email address is required.</label> <label class="error newsletter-error" style="display:none;">Please select at least one newsletter.</label> </form> </div> <div class="subscriber-demographics demographics-form" id="demographics-box-sidebar"></div> <script src="/static/js/subscriberDemographicsForm.js?450216090125"></script> <script> var siteName = 'PharmaVoice' || null; if (siteName) { setupFormCallbackAndCreateFormIfSub(siteName, 'sidebar'); } </script> <div class="sidebar-box" data-box-priority="2"> <h3 class="sidebar-box__header sidebar-box__header--loud"> Most Popular </h3> <ol class="sidebar-box-list sidebar-box-list--ordered"> <li class="sidebar-box-list__item sidebar-box-list__item--ordered flex">  <div class="sidebar-box-list__image-container"> <a class="analytics t-most-popular-sidebar-item-1 hide-small show-large" href="/news/vaccine-makers-earnings-report-flu-rsv-moderna-pfizer-sanofi/740290/"> <img class="sidebar-box-list__image" src="https://imgproxy.divecdn.com/DE1VoMjZwQUnWWMg4MvDi-y5neA9xvoCJs5ghNI1Ocg/g:nowe:0:553/c:4958:2801/rs:fill:600:338:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMDg0MDA2MjYwLmpwZw==.webp" width="600" height="338" srcset="https://imgproxy.divecdn.com/cz1XQZZMZMEj8QdPgPZFyBVLQBjPNvjZM54KnEIbgyA/g:nowe:0:553/c:4958:2801/rs:fill:300:169:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMDg0MDA2MjYwLmpwZw==.webp 300w, https://imgproxy.divecdn.com/DE1VoMjZwQUnWWMg4MvDi-y5neA9xvoCJs5ghNI1Ocg/g:nowe:0:553/c:4958:2801/rs:fill:600:338:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMDg0MDA2MjYwLmpwZw==.webp 600w" sizes="25vw" alt="Pfizer CEO Albert Bourla" loading="lazy" > </a> </div> <div class="sidebar-box-title-container"> <a class="analytics t-most-popular-sidebar-item-1 sidebar-box-list__item-title" href="/news/vaccine-makers-earnings-report-flu-rsv-moderna-pfizer-sanofi/740290/">Challenges mount for vaccine makers </a>  </div> </li> <li class="sidebar-box-list__item sidebar-box-list__item--ordered flex">  <div class="sidebar-box-list__image-container"> <a class="analytics t-most-popular-sidebar-item-2 hide-small show-large" href="/news/veeva-salesforce-split-pharma-biotech-navigate-divorce/739985/"> <img class="sidebar-box-list__image" src="https://imgproxy.divecdn.com/Dc6FN3oQfWJIefemfvtMYDFvb_npXp_Ep0h3V0l6EUc/g:ce/rs:fill:600:338:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy00NzUyNDA5NTIuanBn.webp" width="600" height="338" srcset="https://imgproxy.divecdn.com/ULjRbuXaxGWi04PdaFKVsVOvWeJpupH-QSPjdunLrrs/g:ce/rs:fill:300:169:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy00NzUyNDA5NTIuanBn.webp 300w, https://imgproxy.divecdn.com/Dc6FN3oQfWJIefemfvtMYDFvb_npXp_Ep0h3V0l6EUc/g:ce/rs:fill:600:338:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy00NzUyNDA5NTIuanBn.webp 600w" sizes="25vw" alt="Split heart" loading="lazy" > </a> </div> <div class="sidebar-box-title-container"> <a class="analytics t-most-popular-sidebar-item-2 sidebar-box-list__item-title" href="/news/veeva-salesforce-split-pharma-biotech-navigate-divorce/739985/">Salesforce or Veeva: How drugmakers can navigate the upcoming CRM split </a>  </div> </li> <li class="sidebar-box-list__item sidebar-box-list__item--ordered flex">  <div class="sidebar-box-list__image-container"> <a class="analytics t-most-popular-sidebar-item-3 hide-small show-large" href="/news/crispr-cardio-biotech-scribe-therapeutic/740169/"> <img class="sidebar-box-list__image" src="https://imgproxy.divecdn.com/saIJMRQSX5_qHnHnK1oOIMsWHHc2hRD8iWsd2VKqUlQ/g:ce/rs:fill:600:338:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xODIwNTMzMzM0LmpwZw==.webp" width="600" height="338" srcset="https://imgproxy.divecdn.com/z-Alwza2BhJaBHVkvifNV-h01nBv5RPG2zcz4o0-vsM/g:ce/rs:fill:300:169:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xODIwNTMzMzM0LmpwZw==.webp 300w, https://imgproxy.divecdn.com/saIJMRQSX5_qHnHnK1oOIMsWHHc2hRD8iWsd2VKqUlQ/g:ce/rs:fill:600:338:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xODIwNTMzMzM0LmpwZw==.webp 600w" sizes="25vw" alt="crispr cardio" loading="lazy" > </a> </div> <div class="sidebar-box-title-container">  <a class="analytics t-most-popular-sidebar-item-3 sidebar-box-list__item-title" href="/news/crispr-cardio-biotech-scribe-therapeutic/740169/">CRISPR’s cardio catch-all drives a biotech’s broad potential </a>  </div> </li> <li class="sidebar-box-list__item sidebar-box-list__item--ordered flex">  <div class="sidebar-box-list__image-container"> <a class="analytics t-most-popular-sidebar-item-4 hide-small show-large" href="/news/medicare-drug-pricing-negotiation-ira-trump-pharma-impact/739742/"> <img class="sidebar-box-list__image" src="https://imgproxy.divecdn.com/FLsoEuSvSSBlbS66BU7ZR0teJCQMepdvhdLQt5Ayjwo/g:ce/rs:fill:600:338:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTYzMzA1NDIwLmpwZw==.webp" width="600" height="338" srcset="https://imgproxy.divecdn.com/bbVG-fFcUHvR3RlhSximW1pE4_QirtpdP1mpUsSl4Iw/g:ce/rs:fill:300:169:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTYzMzA1NDIwLmpwZw==.webp 300w, https://imgproxy.divecdn.com/FLsoEuSvSSBlbS66BU7ZR0teJCQMepdvhdLQt5Ayjwo/g:ce/rs:fill:600:338:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTYzMzA1NDIwLmpwZw==.webp 600w" sizes="25vw" alt="Drug pricing" loading="lazy" > </a> </div> <div class="sidebar-box-title-container"> <a class="analytics t-most-popular-sidebar-item-4 sidebar-box-list__item-title" href="/news/medicare-drug-pricing-negotiation-ira-trump-pharma-impact/739742/">Medicare’s next list of drugs for price negotiation could get ‘very interesting’ — and have a bigger impact on pharma </a>  </div> </li> </ol> </div> <div class="sidebar-box hide-small show-large" data-box-priority="4"> <h3 class="sidebar-box__header">Library resources</h3> <ul class="sidebar-box-list"> <li class="sidebar-box-list__item flex"> <div class='sidebar-box-list__icon sidebar-box-list__icon--soft'> <img src="/static/img/lib_icons/webinar-black.svg?141716111021" height="25" width="25" alt="studioID resource icon" loading="lazy"> </div> <div> <div class="label label--soft">Webinar - on demand</div> <a class="analytics t-library-sidebar-item-1 sidebar-box-list__item-title" target="_blank" href="http://resources.industrydive.com/from-research-to-real-world-impact-a-model-informed-drug-development-framework?utm_source=PV&utm_medium=Library&utm_campaign=Certara"> Advancing Health Equity and Innovation with Model-Informed Drug Development </a> <span class="sponsor-label__leading-text secondary-label">Custom content for </span> <span class="sponsor-label__name secondary-label">Certara</span> </div> </li> <li class="sidebar-box-list__item flex"> <div class='sidebar-box-list__icon sidebar-box-list__icon--loud'> <img src="/static/img/lib_icons/trendline.svg?353714160519" height="25" width="25" alt="editorial resource icon" loading="lazy"> </div> <div> <div class="label label--soft">Trendline</div> <a class="analytics t-library-sidebar-item-2 sidebar-box-list__item-title" target="_blank" href="https://www.pharmavoice.com/trendline/rare-diseases/351/?utm_source=PV&utm_medium=Library&utm_campaign=TheMRN"> Inside the growing treatment market for rare diseases </a> <span class="sponsor-label__leading-text secondary-label">Supported by </span> <span class="sponsor-label__name secondary-label">The MRN</span> </div> </li> <li class="sidebar-box-list__item flex"> <div class='sidebar-box-list__icon sidebar-box-list__icon--loud'> <img src="/static/img/lib_icons/whitepaper.svg?102717100918" height="25" width="25" alt="editorial resource icon" loading="lazy"> </div> <div> <a class="analytics t-library-sidebar-item-3 sidebar-box-list__item-title" target="_blank" href="https://www.pharmavoice.com/news/pharma-trends-outlook-2025/738839/"> The PharmaVoice Outlook on 2025 </a> </div> </li> </ul> <a class="analytics t-library-sidebar-all sidebar-box__cta" aria-label="View all library items" href="/library/">View all</a> </div> <div class="sidebar-box js-pressrelease-sidebar-box" data-box-priority=" 6 "> <h3 class="sidebar-box__header">Company Announcements</h3> <ul class="sidebar-box-list"> <li class="sidebar-box-list__item flex js-pressrelease" data-pressrelease-full-url="https://www.pharmavoice.com/press-release/20250206-inizio-accelerates-growth-with-a-trio-of-strategic-leadership-appointments-1/"> <div class="sidebar-box-list__thumbnail-container"> <img alt="Inizio logo" height="48" loading="lazy" src="https://res.cloudinary.com/dmgi9movl/image/upload/dpr_2.0,h_48,w_48/v1738847249/press_release/assets/company_logos/Inizio_Logo_Color_RGB_v02_1_y3t6g9.png" width="48"/> </div> <div class="sidebar-box-title-container"> <a class="sidebar-box-list__item-title analytics t-pr-sidebar-item" href="/press-release/20250206-inizio-accelerates-growth-with-a-trio-of-strategic-leadership-appointments-1/">Inizio accelerates growth with a trio of strategic leadership appointments</a> <span class="secondary-label"> From Inizio </span> </div> </li> </ul> <span class="sidebar-box__cta"> <a class="analytics t-pr-sidebar-all" aria-label="View all press release items" href="/press-release/">View all</a> | <a class="analytics t-pr-sidebar-start" href="/press-release/get-started/">Post a press release</a> </span> </div> <div class="sidebar-box hide-small show-large" data-box-priority="10"> <h3 class="sidebar-box__header">Events</h3> <ul class="sidebar-box-list"> <li class="sidebar-box-list__item flex"> <div class="sidebar-box-list__events-date "> <span class="sidebar-box-list__events-date__day "> 08 </span> <span class="sidebar-box-list__events-date__month "> APR </span> </div> <div class="sidebar-box-title-container__events"> <span class="label label--soft"> Conference </span> <a class="analytics t-events-sidebar-item sidebar-box-list__item-title sidebar-box-list__item-title--spaced" href="https://medicaldeviceregulatoryaffairs.com/" target="_blank" rel="noopener noreferrer">European Medical Device & Diagnostic Regulatory Affairs Conference </a> <span class="label label--weak">Brussels, Belgium </span><br> <span class="label label--weak-italic">Presented by TT Lifesciences</span> </div> </li> </ul> <div class="sidebar-box__cta"> <a class="analytics t-events-sidebar-start " href="/selfservice/event-listings/contact">Promote an event</a> </div> </div> <div class="hybrid-ad-wrapper hide-small show-large"> <div class="hybrid-ad-inner-wrapper"> <div class="hide-small show-large"> <div data-container-ad-unit-id="/21662595662/pharmavoice/pharmavoicehybrid3-desktop"></div> <div id='dfp-hybrid3-desktop'> <script> waitToLoadAds.push(function() { googletag.cmd.push(function() { if (window.dfp_visibility == 'desktop' ) { googletag.display('dfp-hybrid3-desktop'); googletag.pubads().addEventListener('slotRenderEnded', function (event) { var adUnitPath = '/21662595662/pharmavoice/pharmavoicehybrid3'; var onProformative = false; if (onProformative && event.slot.getAdUnitPath() === adUnitPath && !event.isEmpty ) { var adUnitPathWithVisibility = adUnitPath + '-desktop'; var selector = '.pf-comments__ad-wrapper [data-container-ad-unit-id="' + adUnitPathWithVisibility + '"]'; if (!$(selector).closest('.pf-comments__ad-wrapper').hasClass('borders')) { $(selector).closest('.pf-comments__ad-wrapper').addClass('borders') } } }); } }); }); </script> </div> </div> </div> </div> </aside> </div> </div> </div>  <section class="pre-footer"> <section class="signup call-out elevated-footer hide-small hide-medium show-large"> <div class="row"> <div class="large-11 medium-11 medium-centered columns footer-signup" style="display: flex"> <div class="footer-signup__content"> <h3>PharmaVoice stories and insights delivered to your inbox</h3> <p class="subhead">Get the free daily newsletter read by industry leaders</p> <form class="form js-form-email-validate" name="signup" action="/signup/" method="POST"> <label for="id_f1e2ab_email" class="email-input js-email-input"> <span class="screen-reader-text">Email:</span> <input type="email" name="email" placeholder="Work email address" class="email" required id="id_f1e2ab_email"> </label> <input type="hidden" name="signup_box_location" value="elevated_footer"> <input type="hidden" name="signup_initial_url_path" value="/news/pharma-crystal-ball-2025-rd-policy-innovation-drug-clinical/736935/"> <input type="hidden" name="signup_internal_referrer"> <input type="hidden" name="signup_external_referrer"> <input type="hidden" name="referral_url"> <input type="hidden" name="js_enabled" value="0" id="id_f1e2ab_js_enabled"> <ul class="signup-list list-no-bullets"> <li> <label><span class="screen-reader-text">Select user consent:</span></label> <input type="checkbox" name="user_consent" id="id_user_consent-elevated_footer" value="1" class="checkbox"/> <label for="id_user_consent-elevated_footer"> <span class="signup-user-consent_box"> <span> By signing up to receive our newsletter, you agree to our <a href="https://www.techtarget.com/terms-of-use/" target="_blank">Terms of Use</a> and <a href="https://www.techtarget.com/privacy-policy/" target="_blank">Privacy Policy</a>. You can unsubscribe at anytime. </span> </span> </label> </li> </ul> <button class="button button--medium signup-button" type="submit" value="Sign up">Sign up</button> <script type="module" src="/static/js/dist/sendEmailToLytics.bundle.js?325815190225" ></script> <label class="error email_error" style="display:none;">A valid email address is required.</label> <label class="error newsletter-error" style="display:none;">Please select at least one newsletter.</label> </form> </div> <div class="footer-signup__image"> <img class="desktop-image" src="/static/img/pharmavoice/signup-article.png?080016020822" width="275" height="275" loading="lazy" alt="PharmaVoice newsletter example"> </div> </div> </div> </section> <section class="hide-small hide-medium show-large pressrelease-section"> <div class="row pressrelease-footer-box js-pressrelease-footer-box"> <div class="large-12 columns"> <div class="row"> <div class="large-12 columns pressrelease-footer-header"> <h2 class="uppercase-heading-02 pressrelease-footer__heading">Company Announcements</h2> </div> </div> <div class="row"> <div class="large-12 columns pressrelease-footer__cta-links"> <a class="analytics t-pr-edfooter-all" aria-label="View all press release items" href="/press-release/">View all</a> | <a class="analytics t-pr-edfooter-start" href="/press-release/get-started/">Post a press release</a> </div> </div> <div class="row pressrelease-footer__item-list"> <a class="pressrelease-footer-item__anchor analytics t-pr-edfooter-item" href="/press-release/20250206-inizio-accelerates-growth-with-a-trio-of-strategic-leadership-appointments-1/"> <div class="large-3 columns pressrelease-footer-item js-pressrelease" data-pressrelease-full-url="https://www.pharmavoice.com/press-release/20250206-inizio-accelerates-growth-with-a-trio-of-strategic-leadership-appointments-1/"> <div class="pressrelease-footer-item__title"> Inizio accelerates growth with a trio of strategic leadership appointments </div> <div class="pressrelease-footer-item__description"> <div class="pressrelease-footer-item__company"> <div>From Inizio</div> <div class="press-release-date">February 06, 2025</div> </div> <span> <img alt="Inizio logo" class="pressrelease-footer-item__logo" height="50" loading="lazy" src="https://res.cloudinary.com/dmgi9movl/image/upload/dpr_2.0,h_50,w_50/v1738847249/press_release/assets/company_logos/Inizio_Logo_Color_RGB_v02_1_y3t6g9.png" width="50"/> </span> </div> </div> </a> <div class="columns pressrelease-footer-cta large-3"> <p class="pressrelease-footer-cta__heading">Want to share a company announcement with your peers?</p> <p> <a class="pressrelease-footer-cta__link analytics t-pr-edfooter-start-loud" href="/press-release/get-started/"> Get started <span class="call-out-link__arrow">➔</span> </a> </p> </div> </div> </div> </div> </section> <div class="row editors-pick-footer hide-small show-large"> <div class="columns medium-7"> <div class="row"> <div class="columns medium-12"> <div class="editors-pick-footer__title"> Read next </div> <ul class="feed"> <li class="row feed__item"> <div class="medium-5 columns"> <figure class="feed__image-container"> <a class="feed__image analytics t-edfooter-edpicks-1" href="/news/vaccine-makers-earnings-report-flu-rsv-moderna-pfizer-sanofi/740290/"> <img class="" src="https://imgproxy.divecdn.com/7F8wEuhfI0fNaqc2RDTt3t4MpPMWyzoaTSyYGk58m-4/g:nowe:0:553/c:4958:2801/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMDg0MDA2MjYwLmpwZw==.webp" width="1200" height="675" srcset="https://imgproxy.divecdn.com/cz1XQZZMZMEj8QdPgPZFyBVLQBjPNvjZM54KnEIbgyA/g:nowe:0:553/c:4958:2801/rs:fill:300:169:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMDg0MDA2MjYwLmpwZw==.webp 300w, https://imgproxy.divecdn.com/DE1VoMjZwQUnWWMg4MvDi-y5neA9xvoCJs5ghNI1Ocg/g:nowe:0:553/c:4958:2801/rs:fill:600:338:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMDg0MDA2MjYwLmpwZw==.webp 600w, https://imgproxy.divecdn.com/7F8wEuhfI0fNaqc2RDTt3t4MpPMWyzoaTSyYGk58m-4/g:nowe:0:553/c:4958:2801/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMDg0MDA2MjYwLmpwZw==.webp 1200w" sizes="(min-width: 40em ) 25vw, 100vw" alt="Pfizer CEO Albert Bourla" loading="lazy" > </a> <figcaption> <img class="feed__attribution-icon" src="/static/images/info-icon.png?234917240220" width="16" height="16" alt="Image attribution tooltip" tabindex="0"> <div class="feed__attribution">Drew Angerer via Getty Images</div> <img class="feed__attribution-icon" src="/static/images/info-icon.png?234917240220" width="16" height="16" alt="Image attribution tooltip" tabindex="-1"> </figcaption> </figure> </div> <div class="medium-7 columns"> <h3 class="feed__title feed__title--display"> <a href="/news/vaccine-makers-earnings-report-flu-rsv-moderna-pfizer-sanofi/740290/" class="analytics t-edfooter-edpicks-1"> Challenges mount for vaccine makers </a> </h3> <p class="feed__description hide-small show-large">End-of-year earnings reports reveal drugmakers are grappling with declining vaccination rates and an unpredictable Trump administration.</p> <div class="secondary-label"> By Amy Baxter • <span class="secondary-label">Feb. 19, 2025</span> </div> </div> </li> </ul> </div> </div> </div> <div class="columns medium-4"> <div class="row newsposts-by-topic"> <div class="columns medium-12"> <div class="editors-pick-footer__title"> Latest in Biotech </div> <div class="newsposts-by-topic-section"> <ul class="feed"> <li class="row feed__item"> <div class="medium-4 columns"> <div class="feed__image-container"> <a class="feed__image analytics t-edfooter-topics-1" href="/news/immunocore-cfo-business-pharma-eli-lilly-kimmtrak-travis-coy/740447/"> <img class="" src="https://imgproxy.divecdn.com/xl9Dp0xMsbFsSVj-n8dsb_JGJzcPKYbs_Pc7mQwZyJI/g:ce/rs:fill:600:338:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS90cmF2aXNjb3kucG5n.webp" width="600" height="338" srcset="https://imgproxy.divecdn.com/XQBVBx9Pd0bLwKbSnl-ry-buANqIkmfWsi_b0BJYxbw/g:ce/rs:fill:300:169:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS90cmF2aXNjb3kucG5n.webp 300w, https://imgproxy.divecdn.com/xl9Dp0xMsbFsSVj-n8dsb_JGJzcPKYbs_Pc7mQwZyJI/g:ce/rs:fill:600:338:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS90cmF2aXNjb3kucG5n.webp 600w" sizes="25vw" alt="Travis Coy, CFO, Immunocore" loading="lazy" > </a> </div> </div> <div class="medium-8 columns latest-copy"> <div class="display-heading-01"> <a class="analytics t-edfooter-topics-1" href="/news/immunocore-cfo-business-pharma-eli-lilly-kimmtrak-travis-coy/740447/"> Lilly’s former M&A chief scours the landscape for potential deals as Immunocore’s new CFO </a> </div> <div class="secondary-label"> By Michael Gibney </div> </div> </li> <li class="row feed__item"> <div class="medium-4 columns"> <div class="feed__image-container"> <a class="feed__image analytics t-edfooter-topics-2" href="/news/crispr-cardio-biotech-scribe-therapeutic/740169/"> <img class="" src="https://imgproxy.divecdn.com/saIJMRQSX5_qHnHnK1oOIMsWHHc2hRD8iWsd2VKqUlQ/g:ce/rs:fill:600:338:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xODIwNTMzMzM0LmpwZw==.webp" width="600" height="338" srcset="https://imgproxy.divecdn.com/z-Alwza2BhJaBHVkvifNV-h01nBv5RPG2zcz4o0-vsM/g:ce/rs:fill:300:169:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xODIwNTMzMzM0LmpwZw==.webp 300w, https://imgproxy.divecdn.com/saIJMRQSX5_qHnHnK1oOIMsWHHc2hRD8iWsd2VKqUlQ/g:ce/rs:fill:600:338:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xODIwNTMzMzM0LmpwZw==.webp 600w" sizes="25vw" alt="crispr cardio" loading="lazy" > </a> </div> </div> <div class="medium-8 columns latest-copy"> <div class="display-heading-01"> <a class="analytics t-edfooter-topics-2" href="/news/crispr-cardio-biotech-scribe-therapeutic/740169/"> CRISPR’s cardio catch-all drives a biotech’s broad potential </a> </div> <div class="secondary-label"> By Kelly Bilodeau </div> </div> </li> <li class="row feed__item"> <div class="medium-4 columns"> <div class="feed__image-container"> <a class="feed__image analytics t-edfooter-topics-3" href="/news/veeva-salesforce-split-pharma-biotech-navigate-divorce/739985/"> <img class="" src="https://imgproxy.divecdn.com/Dc6FN3oQfWJIefemfvtMYDFvb_npXp_Ep0h3V0l6EUc/g:ce/rs:fill:600:338:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy00NzUyNDA5NTIuanBn.webp" width="600" height="338" srcset="https://imgproxy.divecdn.com/ULjRbuXaxGWi04PdaFKVsVOvWeJpupH-QSPjdunLrrs/g:ce/rs:fill:300:169:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy00NzUyNDA5NTIuanBn.webp 300w, https://imgproxy.divecdn.com/Dc6FN3oQfWJIefemfvtMYDFvb_npXp_Ep0h3V0l6EUc/g:ce/rs:fill:600:338:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy00NzUyNDA5NTIuanBn.webp 600w" sizes="25vw" alt="Split heart" loading="lazy" > </a> </div> </div> <div class="medium-8 columns latest-copy"> <div class="display-heading-01"> <a class="analytics t-edfooter-topics-3" href="/news/veeva-salesforce-split-pharma-biotech-navigate-divorce/739985/"> Salesforce or Veeva: How drugmakers can navigate the upcoming CRM split </a> </div> <div class="secondary-label"> By Michael Gibney </div> </div> </li> </ul> </div> </div> </div> </div> </div> </section> <hr class="footer-hr"> <footer> <div class="custom-article-footer"> <div class="row columns"> <div class="footer-grid"> <div class="footer-links"> <a href="https://www.industrydive.com"> <img class="pub-logo-footer" src="https://d12v9rtnomnebu.cloudfront.net/logo/corporate/ID_black.svg" alt="Industry Dive Logo" height="28" loading="lazy"/> </a> <ul class="social-icon-list social-icon-list__footer"> <li> <a href="https://www.linkedin.com/company/pharmavoice" aria-label="Industry Dive LinkedIn" class="social-icon-footer analytics t-sitefooter-linkedin"> <img src="/static/img/social_icons/article_page/linkedin.svg?092716141024" alt="linkedin icon"> </a> </li> <li> <a href="https://www.facebook.com/PharmaVoice" aria-label="Industry Dive Facebook" class="social-icon-footer analytics t-sitefooter-facebook"> <img src="/static/img/social_icons/article_page/facebook.svg?440116200824" alt="facebook icon"> </a> </li> <li> <a href="https://twitter.com/PharmaVoice" aria-label="Industry Dive X/Twitter" class="social-icon-footer analytics t-sitefooter-twitter"> <img src="/static/img/social_icons/article_page/x.svg?092716141024" alt="x icon"> </a> </li> <li> <a href="https://www.pharmavoice.com/feeds/news/" aria-label="Industry Dive RSS feed" class="social-icon-footer analytics t-sitefooter-rss"> <img src="/static/img/social_icons/article_page/rss.svg?440116200824" alt="rss feed icon"> </a> </li> </ul> </div> <div class="link-wrapper"> <div class="footer-links"> <h4 class="uppercase-heading-01">Explore</h4> <ul class="list-no-bullets"> <li> <a href="/about/" class="analytics t-about-sitefooter">About</a> </li> <li> <a href="/editors/" class="analytics t-editors-sitefooter">Editorial Team</a> </li> <li> <a href="/contact/" class="analytics t-feedback-sitefooter">Contact Us</a> </li> <li> <a href="/signup/?signup_location=footer-list&signup_path=/news/pharma-crystal-ball-2025-rd-policy-innovation-drug-clinical/736935/" class="analytics t-signup-sitefooter">Newsletter</a> </li> <li> <a href="/selfservice/article-licensing/submit/" class="analytics t-licensing-sitefooter">Purchase Licensing Rights</a> </li> <li> <a class="analytics t-pr-sitefooter-all" href="/press-release/">Press Releases</a> </li> </ul> </div> <div class="second-column"> <div class="footer-links"> <h4 class="uppercase-heading-01">Reach our audience</h4> <ul class="list-no-bullets"> <li> <a href="/advertise/" class="analytics t-advertising-sitefooter">Advertising</a> </li> <li> <a class="analytics t-pr-sitefooter-all" href="/press-release/get-started/">Post a press release</a> </li> <li> <a class="analytics t-events-sitefooter-start" href="/selfservice/event-listings/contact">Promote an event</a> </li> </ul> </div> <div class="footer-links"> </div> </div> </div> </div> </div> </div> </footer> <hr class="footer-hr"> <div class="baseline-footer-wrapper"> <div> <div> Industry Dive is an Informa TechTarget business. </div> </div> <div class="baseline-footer"> © 2025 TechTarget, Inc. or its subsidiaries. All rights reserved. | View our <a href="https://www.industrydive.com/industries/">other publications</a> | <a href="https://www.techtarget.com/privacy-policy/">Privacy policy</a> | <a href="https://www.techtarget.com/terms-of-use/">Terms of use</a> | <a href="https://www.industrydive.com/takedown-policy/">Take down policy</a>. <br> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')">Cookie Preferences / Do Not Sell</a> </div> <div class="informa-legal-notice"> This website is owned and operated by Informa TechTarget, part of a global network that informs, influences and connects the world's technology buyers and sellers. All copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. TechTarget, Inc.'s registered office is 275 Grove St. Newton, MA 02466. </div> </div> </div> </div>  <nav class="mobile-menu"> <div class="mm-top-bar"> <button class="mobile-menu-toggle"> <img src="/static/img/menu_icons/close.svg?273117231121" width="20" height="20" alt="close menu"/> </button> <div class="mm-search"> <form action="/search/" method="GET" data-ajax="false"> <label for="search-mobile"> <span class="screen-reader-text">Search</span> <input id="search-mobile" type="search" name="q" placeholder="Search" data-role="none"> </label> <button type="submit" value="" data-role="none" class="search-button-front analytics t-search-navigation-mobile"> <img src="/static/img/menu_icons/search.svg?320116291121" width="15" height="15" alt="search"> </button> </form> </div> </div> <ul class="mm-list list-no-bullets"> <li> <a href="/" class="analytics t-dash-navigation-mobile"> <span>Home</span> </a> </li> <li class="mm-accordion"> <button> <span>Voices</span> <span class="accordion-toggle-arrow"> <img src="/static/img/menu_icons/chevron_down.svg?102717100918" width="16" height="9" alt="down arrow" loading="lazy"> </span> </button> <ul class="list-no-bullets"> <li> <a class="analytics t-voices-navigation-qa" href="/q-and-a">Q&A</a> </li> <li> <a class="analytics t-voices-navigation-profiles" href="/profiles">Profiles</a> </li> <li> <a class="analytics t-voices-navigation-biotechspotlight" href="/topic/biotech-spotlight/">Biotech Spotlight</a> </li> <li> <a class="analytics t-voices-navigation-first90days" href="/topic/first-90-days/">First 90 Days</a> </li> <li> <a class="analytics t-voices-navigation-opinions" href="/opinion">Opinions</a> </li> </ul> </li> <li class="mm-accordion"> <button> <span>Topics</span> <span class="accordion-toggle-arrow"> <img src="/static/img/menu_icons/chevron_down.svg?102717100918" width="16" height="9" alt="down arrow" loading="lazy"> </span> </button> <ul class="list-no-bullets"> <li> <a class="analytics t-topic-navigation-mobile-biotech" href="/topic/biotech/">Biotech</a> </li> <li> <a class="analytics t-topic-navigation-mobile-commercialization" href="/topic/commercialization/">Commercialization</a> </li> <li> <a class="analytics t-topic-navigation-mobile-leadership" href="/topic/leadership/">Leadership</a> </li> <li> <a class="analytics t-topic-navigation-mobile-manufacturing" href="/topic/manufacturing/">Manufacturing</a> </li> <li> <a class="analytics t-topic-navigation-mobile-patient" href="/topic/patient/">Patient</a> </li> <li> <a class="analytics t-topic-navigation-mobile-pharma" href="/topic/pharma/">Pharma</a> </li> <li> <a class="analytics t-topic-navigation-mobile-policy-regulation" href="/topic/policy-regulation/">Policy & Regulation</a> </li> <li> <a class="analytics t-topic-navigation-mobile-research-development" href="/topic/research-development/">Research & Development</a> </li> </ul> </li> <li> <a href="/library/" class="analytics t-library-navigation-mobile">Library</a> </li> <li> <a href="/events/" class="analytics t-events-navigation-mobile">Events</a> </li> <li> <a href="/press-release/" class="analytics t-press-releases-navigation-mobile">Press Releases</a> </li> <li class="mm-accordion"> <button> <span>PharmaVoice 100</span> <span class="accordion-toggle-arrow"> <img src="/static/img/menu_icons/chevron_down.svg?102717100918" width="16" height="9" alt="down arrow" loading="lazy"> </span> </button> <ul class="list-no-bullets"> <li> <a href="https://www.pharmavoice.com/news/pharmavoice-100-nomination-form/611747/" class="analytics t-pv100-navigation-nominate"> Nominate </a> </li> <li> <a href="/news/pv100-pharma-leaders-executives/726233/" class="analytics t-pv100-navigation-current100"> 2024 PV100 </a> </li> <li> <a href="/news/pharmavoice100-pv100-pharma-leaders/690951/" class="analytics t-pv100-navigation-past"> 2023 PV100 </a> </li> </ul> </li> </ul> <section class="signup mm-signup"> <div class="row"> <div class="large-9 medium-10 medium-centered columns"> <h3 class="display-heading-03 display-heading-03--loud">Get PharmaVoice in your inbox</h3> <p class="subhead">The free newsletter covering the top industry headlines</p> <form class="form js-form-email-validate" name="signup" action="/signup/" method="POST"> <label for="id_cce155_email" class="email-input js-email-input"> <span class="screen-reader-text">Email:</span> <input type="email" name="email" placeholder="Work email address" class="email" required id="id_cce155_email"> </label> <input type="hidden" name="signup_box_location" value="integrated_menu"> <input type="hidden" name="signup_initial_url_path" value="/news/pharma-crystal-ball-2025-rd-policy-innovation-drug-clinical/736935/"> <input type="hidden" name="signup_internal_referrer"> <input type="hidden" name="signup_external_referrer"> <input type="hidden" name="referral_url"> <input type="hidden" name="js_enabled" value="0" id="id_cce155_js_enabled"> <ul class="signup-list list-no-bullets"> <li> <label><span class="screen-reader-text">Select user consent:</span></label> <input type="checkbox" name="user_consent" id="id_user_consent-integrated_menu" value="1" class="checkbox"/> <label for="id_user_consent-integrated_menu"> <span class="signup-user-consent_box"> <span> By signing up to receive our newsletter, you agree to our <a href="https://www.techtarget.com/terms-of-use/" target="_blank">Terms of Use</a> and <a href="https://www.techtarget.com/privacy-policy/" target="_blank">Privacy Policy</a>. You can unsubscribe at anytime. </span> </span> </label> </li> </ul> <button class="button button--medium signup-button" type="submit" value="Sign up">Sign up</button> <script type="module" src="/static/js/dist/sendEmailToLytics.bundle.js?325815190225" ></script> <label class="error email_error" style="display:none;">A valid email address is required.</label> <label class="error newsletter-error" style="display:none;">Please select at least one newsletter.</label> </form> </div> </div> </section> </nav> <script src="/static/js/news.js?543416080722" async></script> <script> //Add styling for pdf only if admin button is clicked $(".download-promoted-story-button").click(function(){ $("body").addClass("admin-pdf-styling"); }); $(".js-social-button-print, .js-social-icon-print").click(function(){ if ($("body").hasClass("admin-pdf-styling")){ $("body").removeClass("admin-pdf-styling"); } }); </script> <script type="application/ld+json"> { "@context": "https://schema.org", "@type": "NewsArticle", "headline": "PharmaVoice’s Crystal Ball: Industry shifts in R&D, policy and clinical trials", "image": [ "https://imgproxy.divecdn.com/UzfUm-USjoaswtNqUAyNAMVVtaPkZC5KrXpB9uY4Zzs/g:ce/rs:fill:1200:1200:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTg3Nzk3NzE1XzEuanBn.webp", "https://imgproxy.divecdn.com/pbxwtsx8mJDv63BVE6sLkNqcgq14ykhOkdjF-6yZ66I/g:ce/rs:fill:1200:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTg3Nzk3NzE1XzEuanBn.webp", "https://imgproxy.divecdn.com/BH3I-Mvh5eEUVTqt4CbFYLBZskLlOAkCYr94MXQ7Rhk/g:ce/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTg3Nzk3NzE1XzEuanBn.webp" ], "datePublished": "2025-01-10T07:50:50", "dateModified": "", "author": [ { "@type": "Person", "name": "Meagan Parrish", "url": "www.pharmavoice.com/editors/mparrish/" } ] , "isAccessibleForFree": "False", "hasPart": { "@type": "WebPageElement", "isAccessibleForFree": "False", "cssSelector" : ".gated" } } </script> <script type="module" src="/static/js/dist/article.bundle.js?325815190225" ></script>  <script type="module" src="/static/js/dist/signupValidation.bundle.js?325815190225" ></script> <script type="module" src="/static/js/dist/gtmEvents.bundle.js?325815190225" ></script>  <script type="module" src="/static/js/dist/smartQuotes.bundle.js?325815190225" ></script> <script> // Set cookie if we're on mobile app. Expire if we're not. This affects // which template is used to display the site to the user. $(document).ready(function() { // Get integer value of mobileapp param from URL and default to 0 if it doesn't exist var mobileapp = ''; // Set cookie if mobileapp is 1 or 2 or expire cookie if mobileapp == 0 if (mobileapp == '0') { document.cookie = 'mobileapp=; path=/; expires=Thu, 01 Jan 1970 00:00:01 GMT;'; } else if (mobileapp == '1' || mobileapp == '2') { document.cookie = 'mobileapp=' + mobileapp + '; path=/;'; } // There's no need to immediately load or preload print.css since it's not needed on page // load. Therefore, load it when the document is ready var stylesheet=document.createElement("link"); stylesheet.setAttribute("rel", "stylesheet"); stylesheet.setAttribute("type", "text/css"); stylesheet.setAttribute("media", "print"); if (window.location.pathname.includes('trendline')) { stylesheet.setAttribute("href", "/static/css/print_trendline.css?275715190225"); } else { stylesheet.setAttribute("href", "/static/css/print.css?275715190225"); } document.getElementsByTagName("head")[0].appendChild(stylesheet); }); </script>   <script src="https://ak.sail-horizon.com/spm/spm.v1.min.js"></script> <script type="text/javascript"> $(function() { // Sailthru Personalization Engine Setup var sailthru_setup = { customerId: '12ab35a80530ffa5450add9c09f5de04', domain: 'horizon.pharmavoice.com', spider: true }; if (window.Sailthru) { Sailthru.init(sailthru_setup); } }); </script> </body> </html>

CINXE.COM

PharmaVoice’s Crystal Ball: Industry shifts in R&D, policy and clinical trials | PharmaVoice